Explaining why trial outcomes carry different weight

1. Cycle 101 · November 13, 2026 · follow-on review refinementScreenshot-producer correction prepared; fresh exact-head review pending

   Make the outcome-hierarchy explainer fit its narrowest review state

   Issue #213 / PR #218 remains the sole content/evergreen implementation. No concurrent build, merge, deployment or completion credit exists.

   Hosted findings: exact-head Growth #679 passed. Quality #1079 passed deterministic validation, the production container and HTTP/custom-404 smoke, then found new route-specific failures: the explainer's 4 evidence fields, 9 coverage sections, 15 source links, 4 connected links and 2 keep-reading cards were not declared; the 1,200 × 1,050 image-failure state was not accepted; a long update-history item caused 346-pixel document width at the 320-pixel viewport; and the SVG's bottom checklist copy overlapped and clipped. Its Home illustration-count report traced to a stale visual assertion: current production markup and the deterministic site validator deliberately expose zero canonical editorial-asset IDs there.

   Bounded refinement: page-specific hosted assertions now preserve the exact article contract and capture its missing-image screenshot; update-history items wrap at narrow widths; the SVG checklist is split into non-overlapping two-line prompts without changing its claims; and the Home count matches the established zero-asset contract. No clinical claim, identifier, result, source, outcome hierarchy, safety statement or reader recommendation changed.

   Freshness checkpoint: the first successful local-day pass covers November 12 at 7:58 a.m. through November 13 at 7:59 a.m. America/Denver. It checked PubMed aging/frailty human-study results, ClinicalTrials.gov discovery, FDA biomarker/guidance/press listings and EMA current listings. Recent dapagliflozin/frailty evidence was observational, the resistance-training synthesis predates the interval and reports low or very-low certainty for several outcomes, NCT07597850 had no posted efficacy result, and no interval FDA/EMA change supplied a longevity result. No candidate safely displaced the governed queue; content remains due and this no-safe-story disposition earns no credit.

   Refinement two: Quality #1080 cleared the article-specific responsive failures and reached the focused Evidence Tracker comparison suite. Adding the 66th governed story makes the three-story cap disable 63 unselected controls; the test still expected 62 from the prior 65-story inventory. The final bounded refinement changes that assertion to 63 and nothing else. The two-round review budget is now consumed.

   Evening refinement: Quality #1081 cleared the article and Evidence Tracker checks and reached Search no-JavaScript validation. The candidate page contains the governed 286-record total already established by deterministic validation, but the hosted visual assertion still expected the former production total of 281. The evening run changes only that assertion to 286; it adds no route, record, claim or reader behavior.

   Second evening refinement: Quality #1082 passed the corrected no-JavaScript Search total and reached the filtered Search states, which rendered the candidate's canonical 146 studies and 65 trials while the remaining assertions still expected the former 144 / 64 production inventory. The second and final evening refinement changes only those two filtered-state expectations. The legacy full-site check also emitted the exact 30 Cycle 63/Cycle 82 compatibility failures that the succeeding format-aware gate explicitly accepts; no unexpected legacy failure appeared. The per-run review budget is now consumed.

   Follow-on review refinement: Quality #1083 passed deterministic validation, the production container, HTTP/custom-404 smoke, the full responsive suite, the focused #213 evidence and all Search states. It then stopped because the Cycle 92 verifier requires desktop/mobile/narrow NMN missing-image screenshots while the visual producer omitted the existing NMN page from its screenshot-emission whitelist. This run adds only that existing page name to the whitelist; no route, record, claim, source, result, reader behavior or release threshold changes.

   Verification state and queue: actual production remains healthy on a8499bd at 65 stories / 146 publications / 65 registries / 285 Search records; the branch candidate remains 66 / 146 / 65 / 286. Full local validation, fresh exact-head CI, hosted desktop/mobile/narrow evidence and manual image inspection remain required before any merge decision. Active #213 content/evergreen → ready #215 product only after #213 production-verifies → ready #217 content/news; #183 remains deferred. Ledger stays 13 normal / 9 qualifying content / 4 product. The loop remains unpaused.

2. Cycle 101 · November 12, 2026 · review handoffPR #218 open; exact-head hosted review pending

   Connect one original explainer without duplicating its example records

   Issue #213 / PR #218 is the sole content/evergreen implementation in review. No concurrent implementation, merge, deployment or production verification exists.

   Novelty and reader value: the original explainer joins outcome hierarchy, multiplicity, direct subgroup interaction, analysis populations, non-significance versus equivalence and replication in one seven-question method. Before, readers met those boundaries briefly or story by story; after, they can apply one reusable check to bounded pectin and ACTIVE examples.

   Evidence and source state: all 32 OH/PEC/ACT/FIG/VAL claims remain mapped to 13 current methods or primary-source families after a separate evidence review and same-day release recheck. No checked source changed a claim. The registry routes were reachable but their full live histories were not extractable, so reviewed histories are preserved without inventing a status change.

   Canonical assembly: the branch now proposes 66 stories while retaining 146 unique publications and 65 unique registries. The explainer links to the existing pectin and ACTIVE study/trial records rather than inflating counts; Search contains 277 story/study/trial records and 286 total governed records including organizations and researchers. Home, Latest, Health & function, Topics, Learn, Research, Evidence Tracker, Studies, Trials, Search, recirculation, imagery and both sitemaps are synchronized.

   Verification state: focused validation and full local npm test pass. Hosted QA now explicitly requires the article, its image-failure state, the changed Health & function hub and desktop/mobile/narrow evidence. Docker and local Chromium are unavailable in this runner, so no rendered pass is claimed. Exact-head CI/container/HTTP/accessibility, uploaded screenshot inspection, merge, deployment and production verification remain pending.

   Queue and allowance: active #213 content/evergreen → ready #215 product only after production verification → ready #217 content/news. #183 is deferred. Ledger remains 13 normal / 9 qualifying content / 4 product; this candidate earns no completion credit.

3. Cycle 101 · November 12, 2026 · canonical draft assembly Draft/noindex candidate validated; hosted release gates remain pending

   Map every frozen claim before exposing the explainer to release review

   Issue #213 remains the sole content/evergreen build on agent/issue-213-outcome-hierarchy-explainer. No implementation pull request, second publisher, merge, deployment or production result exists.

   Canonical candidate: the reviewed explainer now occupies its governed article route with noindex,nofollow, creativeWorkStatus: Draft and data-coverage-state="draft". Its original 1,200 × 1,050 SVG uses a hypothetical library-training example, includes a complete text equivalent and contains no real treatment, p-value, probability, rank or evidence score. A staged integration contract reuses the existing pectin and ACTIVE study/trial identities rather than inventing records or counts.

   Evidence mapping and correction: deterministic validation requires exactly the 32 frozen OH/PEC/ACT/FIG/VAL IDs and rejects unknown claims, publication metadata and prohibited shorthand. The released ACTIVE article, canonical study source and rendered Studies comparison now say that booster assignment was randomized within participants eligible after at least eight initial sessions, while the later claims contrast also conditions on eligibility, Medicare linkage and booster exposure/completion. The critique and response remain together; no outcome or inference was strengthened.

   Verification state: the focused candidate validator and full local npm test pass. The repository still reports 65 published stories / 146 publications / 65 registry records / 285 Search records; the draft route raises only the raw HTML page count to 66. Docker is unavailable. Local Chromium could not create its process socket, so this entry does not claim screenshot review. Exact-head hosted desktop/mobile/narrow, accessibility, container, HTTP, release-time source/status and manual visual gates remain mandatory before a PR can merge.

   Queue and allowance: active #213 content/evergreen → ready #215 product only after #213 production-verifies → ready #217 content/news. #183 remains deferred. Ledger remains 13 normal / 9 qualifying content / 4 product with one content completion after the latest product. This draft assembly and correction earn no content or product completion credit.

4. Cycle 101 · November 12, 2026 · bounded freshness checkpoint No safer intervention result displaced the reviewed draft; canonical integration remains next

   Keep interval biomarker and model leads separate from an active explainer

   Issue #213 remains the sole content/evergreen build on agent/issue-213-outcome-hierarchy-explainer. No implementation pull request or concurrent publisher exists. Actual production remains 65 stories / 146 publications / 65 registry records / 285 Search records, with newest actual story dates November 9, November 2 and October 20.

   Freshness checkpoint: the first successful local-day pass covers November 11 at 8:00 a.m. through November 12 at 7:58 a.m. America/Denver, with date overlap so issue assignment, indexing and first-online status were not treated as interchangeable. It checked PubMed identifier/date records, Nature Aging and npj Aging publisher results, bounded ClinicalTrials.gov discovery, FDA's November press index and current EMA/CHMP listings.

   Dispositions: Neurology's November 11 peer-reviewed pTau217 cohort report is a meaningful publication-status lead after a March preprint, but it is disease-specific prognostic/monitoring evidence rather than an intervention or proof that changing the biomarker improves function. A November 11 GeroScience frailty/brain-imaging model was not promoted because the exact publisher/PubMed payload was unavailable and the design remains observational model development without external validation. Nature Aging's retinol–SREBP1–ELOVL6 work reports cells, in-vitro rescue and mouse models rather than a human treatment result. The November 7 DunedinPACNI paper remains an observational biomarker-model lead. FDA lists no November 11–12 relevant action; the EMA CHMP meeting was still in progress without relevant final highlights; bounded registry discovery exposed no exact interval result that cleared source gates.

   Verification state and next action: the reviewed 1,421-word #213 draft and hypothetical figure remain outside public/. Today's checkpoint changes no frozen claim or scientific paragraph and earns no completion credit. Next is the same issue only: canonical article, figure, claim/source/relationship and discovery integration, followed by derived counts, release-time status checks, full deterministic validation and hosted responsive review before one pull request.

   Queue and allowance: active #213 content/evergreen → ready #215 product conditional on #213 production verification → ready #217 content/news. #183 remains deferred. The adoption-forward ledger stays 13 normal / 9 qualifying content / 4 product; one qualifying content completion follows the latest product.

5. Cycle 101 · November 11, 2026 · draft and evidence review All research and draft-review gates complete; canonical integration pending

   Draft the trial-result hierarchy explainer only from frozen claims

   Issue #213 is the sole content/evergreen build on agent/issue-213-outcome-hierarchy-explainer. The required three-item buffer was first restored with #217 content/news; #213 was then claimed alone, leaving #215 product and #217 ready. No implementation pull request or concurrent publisher exists.

   Freshness checkpoints: the November 10 record covers November 9 at 8:12 a.m. through November 10 at 8:04 a.m. America/Denver. Today's first successful local-day pass continues through November 11 at 8:00 a.m. Actual production remains 65 stories / 146 publications / 65 registry records / 285 Search records, with newest actual dates November 9, November 2 and October 20. Date-overlap checks found an interval circadian review, preclinical AIM2/AT2R work, newly listed histology/atlas/metabolic/reprogramming resources, and the observational DunedinPACNI model paper; none is a verified human intervention outcome. Current FDA/EMA listings and bounded registry discovery likewise yielded no result that displaced the queue. ClinicalTrials.gov's exact API/history payload was unavailable, so snippets were not promoted to evidence. The November 4 open-access Prepare for Kidney Care randomized result remains future #217, not another build.

   Research passes 1–3: the overlap audit confirms that current guides mention prespecification and secondary findings but do not teach endpoint hierarchy, multiplicity, subgroup interaction, analysis populations, non-significance versus equivalence and replication together. Full-source verification fixes the current roles and versions of CONSORT 2025, FDA's final October 2022 multiple-endpoints guidance, ICH E9/E9(R1), EMA's still-current effective 2003 multiplicity document and current Cochrane Handbook sections. Exact DOI/PMID/publisher searches found no correction or retraction notice for the named pectin or ACTIVE reports in the bounded check. The frozen pass-3 map now permits 15 methods propositions, seven bounded pectin propositions, seven bounded ACTIVE propositions, two figure propositions and one reader-value proposition. It keeps the ACTIVE critique and response together and forbids calling booster assignment simply nonrandomized, because assignment occurred within an eligible post-randomization subset while the later claims analysis also conditions on Medicare linkage and booster exposure/completion. It also forbids treatment advice, truth scores, universal thresholds, null-as-equivalence wording, unsupported clinical benefit and generic-product substitution.

   Draft and separate evidence review: the reviewed draft is 1,421 narrative words and uses all 32 frozen IDs with no unknown or unannotated narrative claim. Its hypothetical library-training SVG distinguishes primary, ordered key-secondary, exploratory and subgroup branches, then separately asks about analysis population, effect and interval, practical importance and replication. It contains no p-value, probability, treatment claim, ranking or evidence score. The evidence review found no unsupported proposition and identified one bounded final-integration correction: the existing ACTIVE article must replace its shorthand that booster completion was simply nonrandomized with the verified distinction between randomized booster assignment within an eligible subset and later conditioning on eligibility, linkage and exposure/completion. The critique and response remain together.

   Verification state and next action: full local npm test passes after the draft-review record and this Development update. Docker is unavailable in this runner, so no local container build is represented as passing; exact-head CI/container gates remain future release requirements. No public article, canonical record, pull request, merge, deployment or completion credit exists. Next is canonical article/figure/evidence integration from the reviewed draft, followed by fresh derived counts, focused validators, release-time source/status checks and all hosted responsive gates before one PR. The latest released state remains healthy; post-merge Quality #1077 and scheduled Growth #676 passed.

   Queue and allowance: active #213 content/evergreen → ready #215 product conditional on #213 production verification → ready #217 content/news. #183 remains deferred. The adoption-forward ledger stays 13 normal / 9 qualifying content / 4 product; one qualifying content completion follows the latest product, so #213 is eligible and #215 is not yet eligible.

6. Cycle 100 · November 9, 2026 · scheduled review continuation Two-round review budget exhausted; exact low-risk correction recorded for next run

   Reconcile the final Research integration expectation with the governed candidate

   Issue #211 / PR #216 remains the sole implementation. This continuation resumes the exact handoff from the prior run and changes only scripts/visual-qa-intervention-directory.mjs: the /research.html integration expectation now requires 62 links, matching the canonical candidate after the NMN report.

   Verification state: full local npm test passes at 65 stories / 146 publications / 65 registry records / 285 rendered Search records. Exact-head Growth #664 passed. Quality #1067 passed deterministic validation, the production container, HTTP/custom-404 smoke, the legacy full-site boundary, the 65-story Evidence Tracker comparison and the corrected 62-link intervention-directory suite. It then reached the covered-trial comparison suite, whose no-JavaScript check still required the prior 64-record inventory at desktop, mobile and narrow while the governed candidate renders 65.

   Final bounded correction and rerun: refinement round two changed only the covered-trial no-JavaScript expectation from 64 to 65. Full local npm test passed at implementation head 6890c08. Exact-head Growth #665 passed. Quality #1068 passed deterministic validation, the production container, HTTP/custom-404 smoke, the legacy full-site boundary, Evidence Tracker comparison, the corrected intervention directory and the corrected trial comparison, then stopped in scripts/visual-qa-studies-library.mjs. Its randomized-trial state at line 15 and filtered-comparison assertion at line 114 still require 89 records while the governed candidate renders 90 of 146 at desktop, mobile and narrow. The failed run's partial artifacts are not release evidence.

   Budget and next action: both permitted refinement rounds are consumed, so this run makes no third implementation correction and does not merge around the failure. The next scheduled run should change only those two studies-library expectations from 89 to 90, run fresh exact-head Growth and Quality, then download and manually inspect the complete 1280/390/320 evidence before any merge decision. No product, architecture, source, safety or outside-access decision is required; automation stays enabled and the loop remains unpaused.

   Scope and safety: no reader HTML, source, frozen claim, article prose, outcome, dose, safety boundary, conflict disclosure or regulatory interpretation changes. No merge, deployment, production verification or completion credit is claimed.

   Queue and ledger: ready queue remains #213 content/evergreen → #215 product; #215 remains ineligible until #211 and #213 production-verify. #183 remains deferred. Production stays healthy on main 29b2fa6 at 64 stories / 144 publications / 64 registry records / 281 rendered Search records, newest actual story dates November 2, October 20 and October 16. The ledger remains 12 normal / 8 qualifying content / 4 product and zero content since the latest product; content remains due.

7. Cycle 100 · November 9, 2026 · review budget stop Agent review continues next run; no human pause

   Preserve the final bounded Research-link correction instead of merging around it

   Issue #211 / PR #216 remains open after two issue-scoped refinements. Exact-head Growth #662 passed. Quality #1065 passed deterministic validation, the production container, HTTP/custom-404 smoke, legacy full-site responsive QA and all Evidence Tracker comparison scenarios at 1280/390/320.

   Exact remaining defect: the next focused intervention-directory suite found only /research.html failing at desktop, mobile and narrow because its integration manifest still declares expectedCount: 61. The governed candidate renders 62 Research links after adding the NMN report. No other failure was reported before that sequential gate stopped the run. Partial artifacts are retained but are not release evidence.

   Disposition: the review budget is exhausted, so this run does not make a third correction, merge, deploy, award content credit or disable automation. The next scheduled run should update that one issue-scoped expectation to 62, rerun exact-head Growth and Quality, and manually inspect every required screenshot before any merge decision. No product, architecture, source, safety or outside-access decision is required.

   Queue and ledger: ready queue remains #213 content/evergreen → #215 product; #215 remains ineligible until #211 and #213 production-verify. #183 remains deferred. Production stays healthy on main 29b2fa6 at 64 stories / 144 publications / 64 registry records / 281 rendered Search records, newest actual story dates November 2, October 20 and October 16. The ledger remains 12 normal / 8 qualifying content / 4 product and zero content since the latest product; content remains due.

8. Cycle 100 · November 9, 2026 · review refinement two Final bounded refinement; fresh exact-head responsive rerun pending

   Advance the tracker-comparison evidence contract to all 65 governed stories

   Issue #211 / PR #216 remains the sole implementation. Exact-head Quality #1064 again passed deterministic validation, the production container and HTTP/custom-404 smoke. Its legacy full-site responsive boundary then passed, including the newly required NMN default/image-failure captures and all updated inventory surfaces.

   Observed remaining defect: the next focused Evidence Tracker comparison suite still required 64 comparison controls, 61 disabled unselected controls at the three-item cap, and 64 no-JavaScript rows. The canonical tracker and rendered page both contain 65 governed stories, so the suite rejected all comparison scenarios at all three viewports. No focused visual pass or merge is claimed.

   Final bounded correction: refinement round two changes only those three exact comparison-test totals to 65, 62 and 65. It does not change HTML, filters, comparison behavior, sources, frozen claims or article prose. The full local deterministic suite remains required before a final exact-head rerun.

   Queue and ledger: ready queue remains #213 content/evergreen → #215 product; #215 remains ineligible until #211 and #213 production-verify. #183 remains deferred. Production stays healthy on main 29b2fa6 at 64 stories / 144 publications / 64 registry records / 281 rendered Search records, with newest actual story dates November 2, October 20 and October 16. The ledger remains 12 normal / 8 qualifying content / 4 product and zero content since the latest product. Next: fresh exact-head Growth and Quality, then manual inspection of every required 1280/390/320 screenshot. The loop is unpaused.

9. Cycle 100 · November 9, 2026 · review refinement one Hosted deterministic, container and HTTP gates pass; responsive rerun pending

   Bring hosted review contracts forward to the 65-story NMN candidate

   Issue #211 / PR #216 remains the sole content/research-news implementation. Quality run #1063 passed deterministic validation, production-container build and HTTP/custom-404 smoke, then stopped before focused evidence packaging could establish a release result.

   Observed failure: the legacy responsive suite still asserted 64 stories, 144 publications, 64 registry records and 281 Search records, plus the prior Drugs & supplements and Research link totals. Those fixed expectations rejected the candidate’s already validated 65 / 146 / 65 / 285 projection at all three viewports. This is not recorded as a visual pass. The review also found that the new article route was not named in the required evidence manifest and lacked the sourced-article system’s publication-history block.

   Bounded correction: refinement round one updates only the candidate-derived inventory assertions, adds the NMN route’s default and image-failure screenshots at 1280/390/320 to hosted evidence requirements, and adds three dated publication-history facts already supported by the committed research/evidence/status records. No frozen scientific claim, conclusion, dose, recommendation or source status changes.

   Verification and next action: local deterministic tests must be repeated after this correction, then the exact PR head must rerun both required workflows. Every new and changed route screenshot still requires manual desktop/mobile/narrow inspection before merge. No deployment, production verification or completion credit has occurred.

   Queue and ledger: ready queue remains #213 content/evergreen → #215 product; #215 remains ineligible until #211 and #213 production-verify. #183 remains deferred. Production stays healthy on main 29b2fa6 at 64 stories / 144 publications / 64 registry records / 281 rendered Search records, with newest actual story dates November 2, October 20 and October 16. The ledger remains 12 normal / 8 qualifying content / 4 product and zero content since the latest product; content remains due. The loop is unpaused.

10. Cycle 100 · November 9, 2026 · canonical review candidate Local deterministic gates pass; exact-head hosted and visual review pending

    Integrate the 24-week NMN analysis without mistaking target engagement for benefit

    Issue #211 / PR #216 is the sole content/research-news implementation; no concurrent build exists.

    Freshness and status: the first successful local-day checkpoint covers November 8 at 8:02 a.m. through November 9 at 8:12 a.m. America/Denver. The bounded search checked primary papers, PubMed, exact jRCT identifiers through official indexed records and MHLW/JPRN cross-search, and current FDA records. The publisher still displays DOI 10.1038/s41514-026-00482-7 as the September 25 accepted early article without a displayed correction, retraction or expression of concern. jRCTs031220373 remains Complete, target 62, randomized double-blind placebo-controlled, 1,250 mg/day for 24 weeks with hearing change primary; jRCT1030240368 remains Not Recruiting observational secondary use with no new participants. FDA’s current NMN notification records remain process/safety context, not approval or efficacy evidence. Direct exact jRCT opening still returns 403; the official indexed current record, complete history and corroborating cross-search are recorded as the available retrieval path. No retrieved status change requires reopening N01–N23, and this source check is not release clearance by itself.

    Reader value and candidate: the original report distinguishes the registered hearing endpoint, whole-blood NAD target engagement, measured physical function, multiplicity, analyzed populations, adverse events and sponsor roles. It adds the trial-specific result that the hearing-change median was +1.25 dB in both arms while whole-blood NAD rose, without inferring slower aging, clinical benefit, durable safety or supplement advice. The canonical assembly adds exactly one story, two publications and one registry record; it preserves the secondary-use boundary and yields 65 stories, 146 publications, 65 registry records and 285 rendered Search records.

    Verification: three separately recorded pre-prose passes, a separate evidence review and the release-time status recheck are complete. The full local npm test suite passes in the integrated source tree. Local container/browser execution is not yet claimed; exact-head hosted deterministic, production-container, HTTP/custom-404 and responsive evidence must pass, and every changed desktop/mobile/narrow screenshot must be inspected manually before merge. No deployment, production verification or completion credit has occurred.

    Queue and ledger: ready queue is #213 content/evergreen → #215 product; #215 remains ineligible until #211 and #213 both production-verify. #183 remains deferred. Actual production remains main 29b2fa6: 64 stories / 144 publications / 64 registry records / 281 rendered Search records, newest actual story dates November 2, October 20 and October 16. The adoption-forward ledger remains 12 normal / 8 qualifying content / 4 product, zero content since the latest product; content remains due. Next: run exact-head hosted review for PR #216 and inspect all required images. The loop remains unpaused.

1. Cycle 100 · November 8, 2026 · evening complete projection Search, counts and sitemaps assemble externally; exact registry clearance and release gates pending

   Prove the full NMN projection without publishing around the registry gate

   Issue #211 remains the sole content implementation with no pull request or concurrent publisher. This same-local-day continuation reuses the morning freshness checkpoint and does not fabricate another research pass.

   The evening status supplement rechecked the indexed publisher, exact official jRCT URLs and current FDA primary pages. The publisher remains the September 25 accepted early article; the official primary-trial page exposes the same nine-entry history through October 1, 2024; the secondary-use record remains observational, Not Recruiting, target 62 and explicit that no new participants are recruited. FDA’s current notification list and October guidance remain safety/process context, not approval or efficacy evidence. Direct exact jRCT opening still returned 403, so final release-time registry clearance is not claimed.

   A new guarded assembly command copies the repository to an external tree and applies the already reviewed canonical, discovery, evidence, intervention, Search, count and sitemap projections there. It deterministically reaches 65 stories / 146 publications / 65 registries, 276 evidence Search records plus 9 governed entities (285 rendered total), and includes the candidate in both projected sitemaps. The source article remains Draft/noindex and every source-tree public inventory stays unchanged.

   The complete external projection and the unchanged 64-story source baseline both pass their deterministic assembly steps; the source baseline’s full npm test passes. The external tree is intentionally not treated as a release candidate while the registry gate is withheld. No container, hosted visual, exact-head CI, PR, merge, deployment or completion credit is claimed.

   Actual production remains healthy on main 29b2fa6: 64 stories / 144 publications / 64 registries / 281 rendered Search records; newest actual story dates remain November 2, October 20 and October 16. Queue remains #211 content/research-news → #213 content/evergreen → #215 product; #215 stays ineligible until both content items production-verify, and #183 stays deferred. Ledger remains 12 normal / 8 content / 4 product with zero content since the latest product. Next: repeat exact registry retrieval on the next local day or when access clears, then apply the already proven projection and run exact-head, container and hosted responsive gates before one PR.

1. Cycle 100 · November 8, 2026 · freshness and evidence rendering Nine reader surfaces render in isolation; Search, sitemaps and release gates pending

   Extend the guarded NMN candidate through governed evidence surfaces

   Issue #211 remains the sole content implementation with no pull request or concurrent publisher. The first successful local-day checkpoint covers November 7 8:04 a.m. through November 8 8:02 a.m. America/Denver and rechecks the latest actual story dates, primary papers, registry leads and regulator sources without reopening the frozen N01–N23 claim map.

   A November 7 observational DunedinPACE paper is a genuine new biomarker publication but makes no treatment or lifespan claim and does not displace #211. A November 6 vanadyl-sulfate paper is preclinical cell-and-mouse work with no human-benefit or recommendation basis. Third-party registry leads could not replace unavailable exact official records; exact jRCT pages returned an access denial, so the last successful November 7 official checks remain the latest recorded status rather than a fabricated November 8 verification. No bounded FDA or EMA action changed the active story. The NMN publisher page still displays the accepted early article without a correction or retraction notice.

   A new pure renderer projects the reviewed candidate into Evidence Tracker, Studies, Trials and the existing NAD-biology intervention record. The isolated outputs contain 65 tracker rows, 146 publication records, 65 trial records and 54 intervention records; they preserve the canonical randomized-versus-secondary-use boundary, surface the last verified trial date and add the candidate as the second released-story projection under the existing NAD identity rather than inventing a new approach.

   The renderer rejects duplicate application and escapes hostile text. Eight focused valid/rejection tests now pass across canonical integration, article preparation, discovery rendering and evidence rendering. The live source remains Draft/noindex, no public projection changed and this research/build continuation earns no completion credit.

   Actual production remains healthy on main 29b2fa6: 64 stories / 144 publications / 64 registries, with 272 evidence Search records plus 9 governed entities (281 rendered total). Newest actual story dates remain November 2, October 20 and October 16. Queue remains #211 content/research-news → #213 content/evergreen → #215 product; #215 stays ineligible until both content items production-verify, and #183 stays deferred. Ledger remains 12 normal / 8 content / 4 product with zero content since the latest product. Next: complete Search and sitemap assembly, then run full exact-head, container and hosted responsive gates before one PR.

1. Cycle 100 · November 7, 2026 · evening discovery rendering Five reader surfaces render deterministically; evidence assembly and release gates pending

   Render the NMN candidate into reader discovery without publishing it

   Issue #211 remains the sole content implementation with no pull request or concurrent publisher. The morning freshness and same-day source-status checkpoints already cover this local day; this continuation does not fabricate another freshness pass or reopen the frozen N01–N23 scientific claims.

   A new pure renderer projects the reviewed candidate into Home, Latest, Drugs & supplements, Topics and Research. It adds one newest story card, a 65th Latest record classified as randomized evidence spanning biomarkers and function, an 18th category item with matching JSON-LD, the category newest-story link and the Research newest-reporting link. Home remains limited to six reader stories.

   The renderer rejects duplicate application, ambiguous template anchors and hostile display text. It does not write the source tree, change the Draft/noindex article, mutate input inventories, infer a treatment benefit or award completion credit. Six focused valid/rejection tests pass across the canonical integration, article preparation and discovery rendering contracts.

   Actual production remains healthy on main 29b2fa6: 64 stories / 144 publications / 64 registries, with 272 evidence Search records plus 9 governed entities (281 rendered total). Newest actual story dates remain November 2, October 20 and October 16. The 65/146/65 values remain isolated candidate projections only.

   Queue stays #211 content/research-news → #213 content/evergreen → #215 product, with #215 ineligible until both content items production-verify. #183 remains deferred. Ledger stays 12 normal / 8 content / 4 product with zero content since the latest product. Next: complete Evidence Tracker, Studies, Trials, intervention, Search and sitemap assembly, then run full exact-head and visual gates before one PR.

1. Cycle 100 · November 7, 2026 · freshness and guarded candidate assembly No safe interval story; source status reconciled; isolated article/data assembly green

   Prepare the NMN release candidate without publishing around its gates

   Issue #211 remains the sole content implementation with no pull request. The first successful local-day checkpoint covers November 6 8:02 a.m. through November 7 8:04 a.m. America/Denver. It records actual production at 64 stories / 144 publications / 64 registries, plus 272 evidence-projection Search records and 9 governed entity records (281 rendered total); newest actual story dates are November 2, October 20 and October 16.

   No interval candidate cleared the full-source gates. September-dated walking and prehabilitation reports, an August first-online time-restricted-eating pilot, a protocol, a preprint and incompletely reviewed PhenoAge/sarcopenia leads do not displace #211. Newly listed ClinicalTrials.gov candidates remain unverified because exact official records were unavailable through the read-only retrieval path; no efficacy claim was inferred. FDA and bounded EMA checks produced no interval action changing the active story.

   A separate November 7 pre-assembly status reconciliation found the official jRCT randomized record still Complete with 62 participants and hearing change as primary, while the secondary-use record remains observational with no new recruitment. Current FDA primary pages retain the notification-versus-approval boundary. Exact DOI resolution was unavailable in the current path, and the bounded DOI/title check identified no correction notice; this limitation is recorded and actual release on a later local date requires another recheck.

   The new pure candidate preparer rejects stale status review, incomplete evidence review, already published input and missing claims. Its valid path converts only an isolated copy to indexable/Pubished metadata for November 7 and leaves every scientific section byte-identical. Combined with the canonical join contract, the isolated preview passes at 65 stories / 146 publications / 65 registry records. The live article remains Draft/noindex; no canonical inventory, rendered route, sitemap, Search projection or completion ledger changed.

   Queue stays #211 content/research-news → #213 content/evergreen → #215 product, with #215 ineligible until both content items production-verify. #183 remains deferred. Ledger remains 12 normal / 8 content / 4 product, with zero content since the latest product; content remains due. Next: render the complete discovery/evidence candidate, rebuild derived projections and run all exact-head and visual gates before any PR.

1. Cycle 100 · November 6, 2026 · evening source and data integration review Source status unchanged; isolated canonical joins pass; rendered integration pending

   Reconcile release sources and prove the NMN joins before public integration

   Issue #211 remains the sole content implementation with no pull request. The publisher still identifies DOI 10.1038/s41514-026-00482-7 as the September 25 open-access accepted early article. Official jRCTs031220373 remains Complete with 62 participants and hearing change as primary; jRCT1030240368 remains observational secondary use with no new participants. Current FDA primary pages do not change the frozen product, approval, safety or efficacy boundaries. No correction, retraction, endpoint change or regulator action requires reopening N01–N23.

   A new staged integration contract proposes exactly one story/tracker row, two new publication records, one exact link to the existing 2024 synthesis and one canonical jRCT trial record. It explicitly rejects counting the secondary-use registry as another randomized trial or replication, verifies every frozen claim and the separate evidence-review decision, and preserves the existing article, study and trial inputs. The isolated November 6 preview passes at 65 stories / 146 publications / 65 registry records; these are proposed inventories, not publication evidence.

   Focused tests pass for the valid joins and rejection cases covering a missing frozen claim, duplicate story and secondary-use double count. No canonical data, public discovery page, Search projection, sitemap, publication metadata or production route changed. Next: render and validate the complete coherent candidate across article, Home, Latest, category/topic, Research, Evidence Tracker, intervention, Studies, Trials, Search and both sitemaps, then run the full local and exact-head release gates.

   Count audit: main 29b2fa6 contains 64 stories / 144 publications / 64 registry records. The canonical Search evidence projection has 272 records; the rendered page adds 5 governed organizations and 4 researchers for 281 visible records. Neither subtotal nor total is a production change, and the audit correction earns no issue or content credit.

1. Cycle 100 · November 6, 2026 · governed draft Draft and accessible figure complete; separate evidence review passed; release checks pending

   Draft the NMN trial analysis without turning target engagement into benefit

   Issue #211 remains the sole content implementation with no pull request. The unlisted, noindex draft is 1,319 words and uses every frozen claim N01–N23 without adding a new scientific proposition. Its reader value is trial-specific: it reports the registered hearing endpoint, analyzed sets, whole-blood NAD change, measured functional results, multiplicity, adverse events, sponsor roles, linked secondary-use record and current U.S. regulatory boundary rather than repeating the earlier generic NAD overview.

   The original two-lane figure keeps the biochemical and clinical questions separate at desktop and mobile widths. The biochemical lane reports rounded whole-blood NAD medians as target engagement; the clinical lane reports +1.25 dB median hearing change in each arm, p=0.95, q=0.999 and no attributable physical-performance improvement. Complete text follows the image, so its meaning does not depend on image loading or JavaScript.

   A separate sentence-by-sentence evidence review of draft commit b7359df mapped the headline, deck, evidence box, prose, figure, metadata and source list back to every frozen claim. It passed within N01–N23 after adding direct links to the FDA petition response and current NDI list. This is not release clearance: same-day publisher, registry and FDA status checks and all release gates remain open.

   November 6 freshness checkpoint eac0c05 covers the prior local-day interval. A time-restricted-eating pilot carried an August 8 first-online date despite its November issue assignment; a diet secondary analysis and one new observational registry record remain source-gated leads, and current FDA/EMA checks did not identify an interval action changing #211. No second publisher opened.

   Focused site validation passes for 66 pages and 406 required files. XML-specific command-line validation was unavailable because xmllint is not installed; the SVGs still require rendered inspection. Actual production remains 64 stories, 144 publication records, 64 registry records and 272 Search records, newest actual story November 2. Ledger remains 12 normal / 8 content / 4 product with zero content since the latest product. Next: perform same-day release-status checks and governed canonical integration before a PR; no release or credit exists.

1. Cycle 99 · November 5, 2026 · research passes 2–3 Full-source review and atomic claim freeze complete; prose pending

   Freeze what the 24-week NMN trial can support before drafting

   Issue #211 remains the sole content implementation. Research pass 2 fc2cc78 reconciles the complete accepted manuscript, official supplement, initial/current jRCTs031220373 records, linked observational secondary-use record jRCT1030240368, 2024 and 2026 syntheses, sponsor disclosures and current FDA primary records.

   The reviewed evidence separates three results. Sixty-two selected healthy Japanese adults age 65+ were randomized, 60 entered the authors' efficacy population and 58 completed 24 weeks. The prespecified four-frequency hearing change was a median +1.25 dB in each arm (p=0.95; q=0.999), while whole-blood NAD rose markedly in the NMN arm. Measured physical-performance outcomes did not show attributable improvement, and nominal physiological findings did not survive FDR correction. One NMN participant with baseline liver-enzyme abnormalities discontinued after further asymptomatic elevation; the study is too small and short to establish uncommon or long-term safety.

   Research pass 3 db33601 freezes 23 permitted propositions and an accessible two-lane figure contract. It forbids dose advice, supplement recommendations, proof-of-equivalence language, biomarker-to-benefit substitution, anti-aging or lifespan claims, durable-safety claims, unsupported tissue inference and treating the secondary-use study as replication. No scientific prose, figure, public evidence record or pull request exists yet.

   Actual production remains 64 stories, 144 publication records, 64 registry records and 272 rendered Search records; newest actual story date November 2. Adoption-forward ledger remains 12 normal production-verified completions / 8 qualifying content / 4 product, with zero content since the latest product. Working sequence remains #211 content/news → #213 content/evergreen → #215 product; #215 remains ineligible until both content items production-verify. #183 remains deferred. No completion credit or human pause.

1. Cycle 99 · November 5, 2026 · research pass 1 Discovery and scope recorded; full-source review pending

   Separate the NMN trial's registered outcome from its blood-metabolite result

   Issue #211 is the sole content implementation. Its novelty is trial-specific: the existing July NAD overview explains a general biomarker-versus-benefit boundary, while this September 25 paper requires a new reconciliation of the registered hearing endpoint, 24-week analysis populations, missingness, multiplicity, harms and sponsor roles. Repeating the earlier conclusion alone would not qualify.

   Freshness checkpoint 14aba02 covers November 4 at 8:04 a.m. through November 5 at 8:04 a.m. America/Denver. It identified the November 4 Lancet Prepare for Kidney Care phase 3 result (PMID 42982076) as a material future lead requiring its full paper, supplement and ISRCTN history; seven bounded ClinicalTrials.gov first-posted aging/frailty/sarcopenia records had no posted results, and no relevant interval FDA or EMA action surfaced. No second publisher opened and no candidate earned credit.

   Research pass 1 a209357 verifies DOI 10.1038/s41514-026-00482-7, publisher first-online date September 25 and current jRCTs031220373 identity, including its registered hearing primary outcome and target sample of 62. Direct PDF retrieval returned an authorization application rather than the manuscript, and the linked secondary-use record remains unresolved. No PMID was found, none is invented, and no scientific prose or claim map exists.

   Actual production remains 64 stories, 144 publication records, 64 registry records and 272 rendered Search records; newest actual story date November 2. Adoption-forward ledger is 12 normal production-verified completions / 8 qualifying content / 4 product, with zero content since the latest product. Ready queue after the claim is #213 content/evergreen → #215 product, with #215 ineligible until #211 and #213 both production-verify. #183 remains deferred.

1. Cycle 98 · November 4, 2026 · review refinement 2 Second and final bounded refinement prepared; exact-head rerun pending

   Align two legacy indexability checks with the rendered routes

   Issue #207 / PR #214 remains the sole product implementation. Exact head f1e62e4 passed Growth. Quality again passed deterministic validation, production-container build and HTTP/custom-404 smoke before legacy responsive QA reported Search and Research at all three viewports. Readback confirmed refinement one recorded—but did not actually commit—the intended Search assertion update. The unchanged Research route exposes the governed index,follow form while its legacy check incorrectly required the optional large-image suffix.

   Refinement two changes only those test contracts: Search now requires the issue's exact index,follow,max-image-preview:large directive, while Research accepts a robots value beginning with index,follow. It does not change route markup, hierarchy, metadata, ranking, privacy behavior, source data, medical content or claims. This is the second and final refinement round for this iteration; no merge can occur unless a fresh exact-head run passes and every required hosted screenshot is inspected manually.

   The November 4 bounded freshness checkpoint and its primary-source dispositions remain recorded in refinement one below. Actual production remains healthy on bb5d08c: 64 stories, 144 publication records, 64 registry records and 281 Search results; newest actual story date November 2. Ready queue remains #211 content/news → #213 content/evergreen. Ledger remains 11 normal / 8 content / 3 product; #207 earns no product completion before merge, deployment and production verification. #183 remains deferred.

1. Cycle 98 · November 4, 2026 · review refinement 1 One bounded hosted-QA contract correction complete locally; exact-head rerun pending

   Reconcile the intended Search preview directive with legacy responsive QA

   Issue #207 / PR #214 remains the sole product implementation. Exact head e0bc743 passed Growth, deterministic validation, production-container build and HTTP/custom-404 smoke. Hosted responsive QA then stopped because the legacy Search contract still required the prior exact index,follow robots value while the issue intentionally adds max-image-preview:large. The rendered page already contains the new governed value. Refinement one changes only that stale legacy assertion; no route markup, ranking, privacy behavior, medical content or source record changes.

   Freshness checkpoint: the bounded November 3 at 8:05 a.m. through November 4 at 8:04 a.m. America/Denver interval checked recent PubMed records, ClinicalTrials.gov discovery and FDA surrogate-endpoint context. PMID 42570448 was first online August 8 and is a 30-person cancer-support pilot with feasibility primary outcomes and no between-group fatigue, frailty or rhythm effect; PMID 42373885 was first online June 29 and remains a FAXAge protocol without results, consistent with current NCT07207044 registry status. DOI 10.1172/JCI205416 was published November 2 and is outside the interval. NCT07912164 was first posted November 3, is not yet recruiting, has no results and uses a disjunctive aging-clock/inflammatory-marker responder definition after antibiotic preparation; it is a registry signal, not safe standalone efficacy news. The FDA surrogate-endpoint record continues to distinguish biomarkers from direct measures of how people feel, function or survive. No interval candidate displaced the governed queue, no second publisher opened and no credit was awarded.

   Actual production remains healthy on bb5d08c: 64 stories, 144 publication records, 64 registry records and 281 Search results; newest actual story date November 2. Ready queue remains #211 content/news → #213 content/evergreen. Ledger remains 11 normal / 8 content / 3 product; #207 earns no product completion before merge, deployment and production verification. #183 remains deferred.

1. Cycle 98 · November 3, 2026 · build handoff Local deterministic checks pass; exact-head hosted review pending

   Harden Home, Latest and Search without changing their reader hierarchy

   Issue #207 / PR #214 is the sole product implementation. Home, Latest and Search now expose a visible-on-focus skip link as their first keyboard control, with one focusable main#main-content target per route. Shared styling preserves 44-pixel target size, strong focus contrast and reduced-motion behavior.

   Conservative static JSON-LD describes Home as a publication website, Latest as a 64-item newest-first collection generated from the canonical published-coverage manifest, and Search as a private browser-local search-results page. It emits no query, ranking, result-count, popularity, recommendation or evidence-score claim. Robots, canonical, Open Graph and Twitter metadata agree, and first-party scripts on these routes no longer block HTML parsing.

   A deterministic route validator checks skip targets, structured-data shape, exact Latest names/order/URLs, metadata agreement, non-blocking scripts and sixteen documented uncompressed HTML/CSS/JavaScript byte ceilings. A new hosted Chromium suite covers default, focused skip-link and compact-menu states at 1280/390/320 plus no-JavaScript Latest and Search. Full local npm test passes. Docker and a local Chromium runtime are unavailable, so container, HTTP/custom-404, rendered accessibility and manual screenshot gates are pending and must not be inferred as passing.

   Actual production remains healthy on bb5d08c: 64 stories, 144 publication records, 64 registry records and 281 Search results; newest actual story date November 2. Ready queue snapshot after the claim: #211 content/news → #213 content/evergreen. Ledger remains 11 normal / 8 content / 3 product; #207 earns no product completion before merge, deployment and production verification. #183 remains deferred.

1. Cycle 97 · November 3, 2026 · freshness and release checkpoint Prior exact head green; audit-only exact-head review pending

   Recheck the frailty explainer and the new-day evidence interval

   Issue #210 / PR #212 remains the sole implementation: qualifying content / original evergreen only after production verification. Its novelty and before/after value are unchanged: the first dedicated comparison of physical phenotype, deficit accumulation and performance-task inputs helps readers stop treating unlike frailty instruments as interchangeable.

   The November 3 release-time check reopened PubMed records for PMID 11253156, 18826625, 8126356, 30312372 and 24138928 and retained the EWGSOP2 and Horvath errata. No claim-changing notice surfaced. No scientific paragraph, population, sample, result, threshold, funding/conflict statement, treatment claim, diagnosis or lifespan inference changed.

   The bounded interval from November 2 at 8:14 a.m. through November 3 at 8:05 a.m. America/Denver checked PubMed, ClinicalTrials.gov and FDA-domain results with September–October overlap. PMID 42912651 was first online October 23 and remains population-specific cirrhosis measurement context; PMID 42785600 was first online September 25 and remains older claims-index context. Possible November 2 NCT03654807 results and NCT07906041 surfaced only as discovery leads because the accessible official registry pages returned application shells. No interval candidate safely cleared the source gates, no second publisher was opened and no credit was awarded.

   Prior exact head 966583af passed Growth and Quality after two bounded count-contract refinements. This audit-only source-date and Development update requires fresh exact-head deterministic, container, HTTP/custom-404 and hosted Chromium checks, followed by manual inspection of every changed route at 1280/390/320. No merge, deployment, production verification or completion credit has occurred.

   Actual production remains main 70af1402 / Deploy 40047331275: 63 stories, 140 publication records, 64 registry identities and 276 Search records; newest actual story dates October 20/16/14. Ready queue snapshot: #207 product only after #210 production-verifies, then #211 content/news. #183 is deferred; #205 canceled/no credit. Ledger remains 10 normal / 7 content / 3 product, one content since the latest product. Loop unpaused.

1. Cycle 97 · November 2, 2026 · review refinement 2 Two bounded hosted-QA refinements complete locally; fresh exact-head review pending

   Keep the frailty explainer in review after the second bounded QA correction

   Issue #210 / PR #212 remains the sole implementation. The first refinement reconciled stale story, publication, tracker and Search totals. Exact-head Growth then passed; Quality again passed deterministic validation, production-container build, HTTP/custom-404 checks and the evidence-comparison suite.

   The second hosted run found one remaining bounded legacy assertion: Research now contains 61 governed links after this explainer, while the intervention-directory integration check still expected 60. Refinement two changes only that expected count. No medical, editorial, accessibility or rendered-site defect was identified by the failure. Full local npm test passes after the correction.

   The two-round review budget is now consumed. Fresh exact-head hosted checks, complete artifact packaging and manual inspection of every changed visible route at 1280/390/320 remain required in the next scheduled iteration. No merge, deployment, production verification or completion credit has occurred. Actual production remains main 70af1402 / Deploy 40047331275: 63 stories, 140 publication records, 64 registry identities and 276 Search records; newest actual story dates October 20/16/14.

   Ready queue snapshot: #207 product only after #210 production-verifies, then #211 content/news. #183 is deferred; #205 canceled/no credit. Ledger remains 10 normal / 7 content / 3 product, one content since the latest product. Loop unpaused.

1. Cycle 97 · November 2, 2026 · review refinement 1Canonical release candidate integrated; bounded hosted-QA refinement complete locally

   Explain why frailty scores can measure different constructs

   Issue #210 / PR #212 is one substantive original content/evergreen outcome. It adds the first dedicated comparison of physical phenotype, deficit accumulation and performance-task inputs, with nineteen frozen claims, instrument-specific populations and denominators, an accessible original figure, and explicit prediction-versus-treatment boundaries.

   The November 2 release-time primary-source check reconfirmed PMID 11253156, 18826625, 8126356, 30312372 and 24138928 and retained the EWGSOP2 and Horvath errata. No claim-changing notice was found in the bounded check; no scientific paragraph, source identity, population, sample, result, threshold, funding/conflict statement, treatment claim or lifespan inference changed.

   Release-candidate integration e170fe7 adds the article and discovery image, applies the canonical story/study/tracker joins and derives 64 stories, 144 publication records, 64 registry identities and 281 Search records. It preserves the frozen 48-story Q3 evidence edition and the distinct 50-story Trials representation denominator. Full npm test passes in the source state, fresh isolated candidate and applied branch state; all 33 committed blobs matched local Git object hashes.

   Exact-head Growth passed. The first hosted Quality run passed deterministic validation, production-container build and HTTP/custom-404 checks, then stopped because legacy responsive assertions still expected the pre-integration story, publication, tracker and Search totals. No medical, editorial or rendered-site defect was identified. Review refinement one reconciles only those bounded test contracts to the canonical 64-story, 144-publication and 281-record inventories; full local npm test passes. Fresh exact-head hosted checks and manual inspection of every changed visible route at 1280/390/320 remain required.

   Docker and local Chromium are unavailable, so this is not release clearance. No merge, deployment, production verification or completion credit has occurred.

   Actual production remains main 70af1402 / Deploy 40047331275: 63 stories, 140 publication records, 64 registry identities and 276 Search records; newest actual story dates October 20/16/14. Ready queue snapshot: #207 product only after #210 production-verifies, then #211 content/news. #183 is deferred; #205 canceled/no credit. Ledger remains 10 normal / 7 content / 3 product, one content since the latest product. Loop unpaused.

1. Cycle 97 · November 2, 2026Isolated deterministic candidate green; canonical integration and release checks pending

   Close the staged frailty candidate’s deterministic validation failures

   Issue #210 remains the sole active content/evergreen build. The separate November 2 freshness checkpoint found no new interval story that cleared the source gates; an older October 13 measurement-validation paper was recorded as later context/counterevidence without changing the frozen claims or prose.

   Implementation 14647a1 derives current inventory expectations, protects the frozen 48-story Q3 denominator and distinct 50-story Trials representation denominator, updates the current Start Here tracker link, and gives all seven Cycle 97 unit suites explicit pre-integration fixtures while retaining their negative safety cases. Full source npm test passes. In a fresh isolated October 31 candidate, all 62 test commands pass independently. Thirteen implementation-file GitHub readbacks match local Git object hashes.

   This is not a publication or review handoff. The source article remains Draft/noindex with publicationDate null. Docker and local Chromium are unavailable; coherent current-day canonical integration, source/status and metadata reconciliation, one implementation PR, exact-head hosted CI/container/HTTP/custom-404, every-changed-route 1280/390/320 evidence and manual screenshot inspection remain pending. No merge, deployment, production verification or completion credit.

   Actual production remains main 70af1402 / Deploy 40047331275: 63 stories, 140 publication records, 64 registry identities and 276 Search records; newest actual story dates October 20/16/14. Ready queue snapshot: #207 product only after #210 production-verifies, then #211 content/news. #183 is deferred; #205 canceled/no credit. Ledger stays 10 normal / 7 content / 3 product, one content since the latest product. Loop unpaused.

1. Cycle 97 · November 1, 2026Candidate copy and bounded source-status reviews complete; integration and release checks pending

   Explain why a changed frailty score needs its measurement context

   Issue #210 remains the sole active build: original content / evergreen. Three separately committed research passes preceded the substantial original article, nineteen frozen claims and accessible measurement-input figure. Separate evidence reviews preserve the original populations, protocols, missingness and prediction-versus-treatment boundaries.

   Restored the branch for complete local validation and corrected stale Development assertions that still required the resolved incident and canceled queue. Full npm test now passes. Added exact-width article/figure browser checks for normal, no-JavaScript, missing-figure and compact-navigation states, and corrected the article navigation marker. Browser execution and manual image inspection remain pending; the new checks are not a visual pass.

   A separate October 30 evening review checked the final candidate article, figure text, metadata and staged discovery descriptions against all nineteen frozen claims. Current primary-source records retained both known corrections; no claim-changing notice was identified in the bounded check. Full npm test passes after making the review-gate fixture independent of changing live review status. Added a deterministic six-surface discovery preview for Home, Latest, Health & function, Topics, Learn and Research, with matching Latest metadata, preserved older cards and guarded category counts. Focused rejection/escaping tests and full npm test pass. The preview does not publish or write discovery pages; tracker/study rendering and complete release assembly remain pending. Added a tested Studies/Evidence Tracker renderer and a non-publishing assembly that combines nine discovery and evidence surfaces. Its reviewed-date preview passes Latest and Tracker validators and local HTTP checks on eleven routes/assets; Search retains all nine organization/researcher records. A later-date preview exposed stale source-review metadata, which remains a release gate. Chromium is unavailable locally; no rendered pass is claimed. Prepared intended-date byline, social/schema metadata, both sitemaps and reciprocal outcome reading links in an isolated release candidate after an actual October 31 source-status recheck. The previously blocked correction text is now readable. Full source-branch tests pass. Running every assembled-candidate command separately found 33 of 60 passing; missing recirculation/image records, metadata/count integration, reproducible outcome rendering and fixture updates remain open. Corrected the six-card Home and eleven-guide Learn contracts. This is not release clearance or a production change. Completed isolated discovery-image, related-reading and author/schema contracts without changing scientific paragraphs. The governed outcome builder now reproduces the measurement-context link. Recirculation, launch metadata and outcome validators now pass in the candidate; all candidate commands were rerun and 36 of 61 pass. Remaining count/metadata/route/illustration and fixture failures are explicitly recorded. Full source-branch tests pass; no release clearance, PR or deployment is claimed. November 1 freshness research found no newly cleared story and did not advance source-review dates. Synchronized current story/category/publication labels, reader-path inventory and the Trials library denominator while preserving source dates, scientific fields and all registry records. Updated historical projection expectations to current inventories without changing medical/sample assertions. Coverage, category, illustration, Start Here, Trials and five historical validators now pass in the candidate. Validation is 46 of 62 commands passing, with sixteen failures still explicitly recorded. Full source-branch checks pass; no release clearance or deployment is claimed. Canonical study and discovery joins remain staged. Complete rendered discovery integration, derived counts, sitemaps, same-day release metadata/status reconciliation, exact-head CI/container/custom-404 and inspected desktop/mobile/narrow screenshots remain pending. No implementation PR exists; see the pull-request list. Separate verification work adds no medical claims or publication credit.

   October 31 bounded freshness research records primary-source leads and retrieval limits without starting another build. Direct production Home returned HTTP 200; no deployment or full production re-verification occurred. Actual released inventory remains 63 stories, 140 publications, 64 registry identities and 276 Search records; latest actual story dates October 20/16/14.

   Ready queue: #207 product only after #210 production-verifies, then #211 content/news. #183 deferred; #205 canceled/no credit. Ten normal completions: seven content, three product; one content since the latest product. No completion credit for this continuation. The loop remains unpaused.

2. Cycle 96 · October 25, 2026Closed without publication; no completion credit

   Preserve a no-safe-story research disposition

   Issue #205 was closed as not planned after primary-source uncertainties remained unresolved. Its preserved research branch was not merged, no article was published, and no completion credit was awarded. The loop remains available for independent source-reviewed coverage.

3. Cycle 95 repair · October 24, 2026Repair production-verified; ordinary loop subsequently resumed

   Keep discovery labels aligned with actual records

   Issue #201 / PR #209 repairs stale labels found after PR #208 deployed.

   • Canonical data and rendered records already contain 63 stories, 140 publications and 64 unique trials. Research retained the prior trial total; Studies retained a static numerator and denominator while JavaScript updated only the numerator.
   • Both static labels now derive from their governed record inventories. Regression checks reject stale full labels, and responsive browser checks cover filtering, clearing and JavaScript-disabled counts.
   • The new deterministic regressions first failed on the released labels and pass after synchronization. The controller records successful release verification for merged PR #209 on main 70af1402e72f20345eae1446ece8aacd7cd46710, including Deploy 40047331275. Issue #201 is closed; its original content outcome received completion credit only after the repair passed verification.
   • This repair earns no separate completion credit. The owner subsequently approved resumption in controller #3; the prior incident pause is superseded.
4. Cycle 95 · October 20, 2026 · release reviewEvidence reviewed; release checks pending

   What a four-week pectin pilot did—and did not—show

   Issue #201 / draft PR #208 is the sole active implementation.

   • Novelty and reader value: adds original reporting on PMID 42803883 and NCT06955975, including the null paper-defined inflammatory result, secondary and exploratory signals, retrospective registration, public outcome-hierarchy discrepancy, safety limits, funding and complete conflicts.
   • Evidence state: three pre-prose research passes and a separate claim-by-claim evidence review are complete. The full paper, three publisher supplements, registry versions 1–2, Crossmark, counterevidence and disclosures were checked; the frozen map forbids treatment, mechanism, frailty-reversal, prevention, healthspan, lifespan and supplement-advice claims.
   • Verification state: article, two accessible original SVGs, research note, claim map and governed projections are on the draft branch. Deterministic validation, production-container and HTTP/custom-404 smoke checks passed; the release-time source/status recheck found no claim-changing update. A first hosted render completed and exposed bounded stale count assertions plus one visible Latest count, now corrected for exact-head rerun. Final exact-head CI and manual hosted desktop/mobile/narrow inspection, merge, deployment and production verification are not complete.
   • Freshness checkpoint: the October 19–20 bounded search checked PubMed, ClinicalTrials.gov and FDA records. No newer safer story displaced the ordered queue.
5. Cycle 94 · October 19, 2026 · releasedProduction verified

   Real organization and researcher directories

   Issue #199 / PR #206 released at commit 2c7d2ae.

   • Five governed organization records and four governed researcher records are indexed and filterable, with relationship roles, provenance, unknown states and correction states kept explicit.
   • Production revision moreyears-news-00106-6mj serves 273 Search records: 62 stories, 139 studies, 63 trials, five organizations and four researchers.
   • This product completion brought the adoption-forward ledger to 9 normal outcomes: 6 qualifying content and 3 product.
6. Cycle 93 · October 17, 2026Independent review

   Cutting protein did not raise blood-cell autophagy in one trial

   Issue #197 adds one substantive original Research Analysis after three separately recorded research passes, a frozen atomic claim map and a separate evidence review. PR #202 is the sole active release candidate.

   • Novelty and reader value: this is the site’s first direct report on a controlled human protein-restriction experiment measuring autophagic flux. It turns a mechanistic longevity idea into an interpretable null primary estimate while keeping blood-cell measurement, four-week exposure and healthy-adult population boundaries visible.
   • Records DOI 10.1016/j.clnu.2026.106778, PMID 42721581, ACTRN 12623000260628, 74 randomized participants, 63 completers, the 61-participant adjusted primary analysis, the estimate and confidence interval, preprint-to-journal status, funding, assay-patent conflict, limitations and regulatory/safety boundaries.
   • Raises the staged library to 62 canonical stories, 139 covered publications, 63 trials, 53 covered intervention/exposure records and 264 Search records. Verification state: prior exact-head CI, production-container, HTTP/custom-404 and hosted responsive gates passed after two bounded figure and image-failure corrections. This Development-state correction requires fresh exact-head CI and replacement Development plus article image-failure inspection before merge; deployment and production verification remain pending.

   Ready queue: #199 (product · evidence-strength language and prominence), then #201 (content · evergreen pectin/frailty explainer). #183 remains deferred scheduling backlog. Adoption-forward ledger remains 7 normal completions: 5 content, 2 product; #197 is active and earns no credit until merge, deployment and production verification. Next eligible action is independent review of #197; pause state: none.

7. Cycle 92 · October 14, 2026Build handoff

   A review found healthspan signals—and no common effect

   Issue #195 / PR #200 adds one substantive original Research Analysis after three separately recorded pre-draft research passes, a frozen twenty-claim map and a separate post-draft evidence review.

   • Novelty and reader value: existing coverage explains exercise, calorie restriction and individual outcomes separately. This report shows how 15 randomized studies tried to combine function and well-being, why the review could count study-level signals but could not estimate a common effect, and why those counts do not establish a treatment ranking or added healthy years.
   • Records DOI 10.1093/gerona/glag133, PMID 42172592, PMCID PMC13290488, PROSPERO CRD420251015780, 4,656 participants, populations, measures, intervention overlap, risk of bias, absent formal certainty grading, limitations, funding, conflicts and publication status.
   • Raises the staged library to 61 canonical stories, 138 covered publications, 62 trials and 261 private Search records; connects the article to Health & function, Evidence, Studies, Search, exercise and CALERIE without changing any prior conclusion.
   • Verification state: deterministic projections and the separate claim-by-claim evidence review pass with no unsupported claim. Release-time publisher, bibliographic, registry and notice recheck, full exact-head CI, hosted 1280/390/320 Chromium and accessibility review, independent screenshot inspection, deployment and production verification remain pending.

   Freshness checkpoint — October 14: the bounded October 13 8:18 a.m.–October 14 8:04 a.m. MDT interval checked recent PubMed aging and healthspan records, ClinicalTrials.gov candidates, FDA materials and the governing systematic review. The latest actual production story dates are October 13 for the ASPREE analysis and October 10 for the aging-clock report. Recent tissue, senescence and biomarker candidates were preclinical, observational or less mature; no safer or more useful story displaced #195.

   Allocation and queue: the adoption-forward ledger remains 6 normal / 4 qualifying content / 2 product, with zero qualifying content completions since the most recent product. Active: #195 (content · fresh reporting). Dependency-ready next: #197 (content · fresh reporting), then #199 (product · organization and researcher directories). #183 remains deferred scheduling backlog. Next eligible action is independent review of #195; pause state: none.

8. Cycle 91 · October 13, 2026 Production verified

   Side-by-side comparison for the Human Longevity Evidence Tracker

   Issue #193 / PR #198 adds progressive-enhancement selection for up to three exact released story identities on the existing Evidence Tracker.

   • Projects title, route, topic, evidence scope, intervention or exposure, population or model, design and comparator, measured outcome, released bottom line, not-established boundary and verification date directly from the canonical tracker data.
   • Normalizes shareable URL state, deduplicates and caps selections, keeps filtered-out selections visible with an honest recovery path, and provides removal, clear-all and local copy-link states.
   • Preserves all 60 governed rows and article links without JavaScript; adds no score, treatment ranking, cross-study synthesis, storage, telemetry, external request or new medical claim.
   • Verification state: exact-head deterministic, production-container, HTTP/custom-404 and hosted responsive gates passed; PR #198 merged as 01a275a4dd95dd0bc9edc0dff89bc69a484cd82f. Deploy #99 and post-merge Quality #879 succeeded, and the changed production routes were verified before Cycle 92 began.

   Freshness checkpoint — October 13: the bounded 8:08–8:18 a.m. MDT pass found 60 actual production stories, led by the October 13 ASPREE analysis and October 10 aging-clock report. It checked recent PubMed aging results, the new lower-protein/autophagy human randomized trial and ANZCTR identity, recent ClinicalTrials.gov candidates and FDA nutrition-label context. #197 retains the new human null-result story; a small pectin/frailty RCT remains deferred pending fuller review.

   Allocation and queue: the production ledger is 5 normal / 4 qualifying content / 1 product, with two content completions since the last product. Active: #193 (product; no content credit). Dependency-ready next: #195 then #197, both content/news. #183 remains deferred; pause state: none.

9. Cycle 90 · October 12, 2026Exact-head review

   ASPREE’s five-part healthspan composite stayed near the null

   Issue #191 / PR #196 adds one substantive original Research Analysis after three separately recorded pre-draft research passes and a frozen twenty-claim map.

   • Novelty and reader value: existing ASPREE coverage separates disability-free survival, cardiovascular events and major bleeding, and later cancer follow-up. This increment explains the newly reported five-part first-event composite, why 2,045 baseline diabetes cases matter, and why a near-null aggregate cannot establish component effects, equivalence or a universal measure of healthspan.
   • Records DOI 10.1093/ageing/afag218, PMID 42497096, PMCID PMC13398386, trial NCT01038583, the July 2/July 24 publication-date discrepancy, population, secondary-analysis maturity, absolute person-time rates, HR 0.98 (95% CI 0.92–1.05), sensitivity analyses, limitations, funding, no declared author conflicts, Bayer’s in-kind tablet supply and bleeding context.
   • Raises the staged library to 60 canonical stories, 137 studies, 62 trials and 259 private Search records; connects the article to Health & function, low-dose aspirin, Evidence, Studies, Trials, Search and the existing ASPREE stories without changing their conclusions.
   • Verification state: the separate claim-by-claim evidence review and October 12 publisher, bibliographic, registry, primary-trial, FDA safety, funding and disclosure recheck pass with no unsupported claim or claim-changing update. The sourced-article DOM and stale visual-total corrections are prepared. Exact-head Growth #447 passed. Quality #865 passed repository, production-container and HTTP/custom-404 smoke gates, then correctly showed that the three repaired ASPREE pages had disappeared from the legacy failure set while the wrapper still required those obsolete exceptions; only those three compatibility entries are retired in refinement 2. Fresh exact-head CI, production-container and HTTP/custom-404 smoke, hosted 1280/390/320 Chromium and accessibility review, independent manual screenshot inspection, deployment and production verification.

   Freshness checkpoint — October 12: the bounded October 11 7:56 p.m.–October 12 8:32 a.m. MDT interval rechecked Oxford Academic, PubMed/PMC identity, NCT01038583, original ASPREE reports, FDA aspirin safety language, funding and disclosures. No linked notice, claim-changing registry or safety update, or safer competing story displaced #191. ASPREE’s September long-term-follow-up announcement remains background only. The latest actual production story publication date remains October 10, 2026; October 11 is staged metadata and earns no credit before production verification.

   Allocation and queue: the adoption-forward ledger remains 4 normal / 3 qualifying content / 1 product, with one qualifying content completion since the last product item. Active: #191 (content · fresh reporting). Dependency-ready next: #193 (product · Evidence Tracker comparison, ineligible until #191 completes), then #195 (content · multidimensional-healthspan systematic-review analysis). #183 remains deferred scheduling backlog. Next eligible action is fresh exact-head CI and rendered review of #191; pause state: none.

10. Cycle 89 · October 10, 2026Build handoff

    Sex-specific aging clocks: model differences without a clinical-test claim

    Issue #189 / PR #194 adds one original research brief after three separately recorded pre-draft research passes, a frozen fourteen-claim map and a separate evidence review.

    • Novelty and reader value: before this increment, the publication explained general clock limits, a CT-derived age model and an exploratory proteomic-clock analysis. The new brief shows what thirty-eight sex-stratified multimodal models predicted, why an age gap is a model residual, where overfitting appeared, why downstream associations are not individual forecasts, and why reuse of A4 data does not reverse that trial’s null solanezumab result.
    • Records DOI 10.1038/s41591-026-04662-6, PMID 42749890, first-online date September 16, 2026, linked trial NCT02008357, explicit population/model and evidence maturity, limitations, funding/conflicts, safety/regulatory context and exact study/trial/search relationships.
    • Raises the staged library to 59 canonical stories, 136 studies, 62 trials and 257 private Search records while keeping actual stories and plain-language categories ahead of workflow material.
    • Verification state: full deterministic validation and the dedicated Cycle 89 gate pass locally. The independent October 10 release-time publisher, publication-status, PubMed, A4 registry/result and bounded FDA biomarker-qualification recheck found no correction, retraction, registry change, regulatory qualification or claim-changing update. Docker is unavailable in this runner. Exact-head CI, production-container and HTTP/custom-404 smoke, hosted 1280/390/320 Chromium captures, accessibility, independent manual screenshot review, deployment and production verification remain pending.

    Freshness checkpoint — October 10: the bounded 08:03–08:12 a.m. MDT read-only interval checked recent PubMed and publisher records, ClinicalTrials.gov, FDA/regulator results, Crossmark and the governing paper. The paper remains current; no safer or more mature human-outcome report displaced #189. The latest actual production story publication date remains October 2, 2026; October 10 is staged metadata and earns no credit before production verification.

    Allocation and queue: the adoption-forward ledger remains 3 normal / 2 qualifying content / 1 product, with zero qualifying content completions since the last product item. Active: #189 (content · fresh reporting). Dependency-ready next: #191 (content · fresh reporting), then #193 (product · Evidence Tracker comparison, ineligible until #189 and #191 both complete). Next eligible action is independent review of #189; pause state: none.

11. Cycle 88 · October 9, 2026Build handoff

    Outcome guides keep twelve released stories in their evidence lanes

    Issue #181 / PR #192 adds static outcome guides for heart and circulation, brain and cognition, and strength, bones and independence. Each page is generated from the exact governed Start Here membership and order, Evidence at a glance fields, and published-coverage metadata; no scientific summary is hand-maintained.

    • Shows title, format, date, intervention or exposure, population or model, design and comparator, measured outcome, released bottom line, explicit not-established boundary, evidence scope, verification date and the governed reading-path reason together for each of twelve stories.
    • States that inclusion, counts and sequence are not evidence scores, treatment rankings, recommendations, diagnoses, individual forecasts or permission to treat unlike outcomes as interchangeable.
    • Connects the guides beneath existing story/category discovery in Start Here, Topics and Aging Biology; Home, Latest and primary navigation remain unchanged.
    • Verification state: deterministic source/render, identity, invalid-state, metadata, sitemap and integration checks are included. Full exact-head CI, production-container smoke, hosted 1280/390/320 Chromium review, accessibility review, deployment and production verification remain pending.

    Freshness checkpoint — October 9: the bounded read-only interval since October 8’s evening checkpoint checked recent PubMed aging results, ClinicalTrials.gov aging/longevity records and FDA materials. October-dated search results were older first-online reviews, protocols, observational cohorts or preclinical work; no coherent new human-outcome report displaced the governed queue. The latest actual production story date remains October 2, 2026. Content remains due after this product item.

    Allocation and queue: adoption-forward ledger remains 2 normal / 2 qualifying content / 0 completed product until release. Active: #181 (product). Dependency-ready next: #189 and #191, both fresh-reporting content. Next eligible action is independent review of #181; pause state: none.

12. Cycle 87 · October 2, 2026Build handoff

    Absolute and relative risk, with trial outcomes kept on their reported scales

    Issue #187 / PR #190 adds a substantive original evergreen explainer after three separately recorded research passes and an independent claim-by-claim evidence review. The fictional figure is labelled as teaching material; SPRINT and ASPREE populations, endpoints, denominators, follow-up, intervals, funding, harms and status checks remain explicit. The release candidate earns no completion credit until merge, deployment and production verification.

    Verification state: Growth #426 passed at exact head. Quality #844 passed deterministic validation, production-container build, HTTP/custom-404 smoke and the full hosted Chromium matrix, including the corrected 254-record Search no-JavaScript state. Manual review of the uploaded 1280/390/320 article images then found a real presentation defect hidden by the machine checks: above the 340-pixel single-column breakpoint, the four-column worked-example table occupied the numbered section’s 42-pixel grid column, creating one-character columns and excessive page height. The final bounded refinement places the table in the article content column while retaining the accessible stacked-card presentation at compact widths. Fresh exact-head CI and focused visual reinspection remain required before merge; production verification remains required before completion credit.

    Freshness checkpoint — October 7: The bounded October 6 07:56–October 7 08:08 MDT interval rechecked SPRINT (PMID 34010531; NCT01206062), ASPREE (PMID 30221597; NCT01038583), Cochrane Handbook v6.5 Chapter 15, #189’s September 16 first-online paper (PMID 42749890), and current FDA biomarker-qualification material. No claim-changing correction, registry or regulator update was found. The latest actual production story date remains October 1; the explainer’s October 2 date is staged metadata and earns no completion credit before production verification.

    Allocation and queue: Adoption-forward ledger remains 1 normal completion / 1 qualifying content / 0 product. Active: #187 (content · original evergreen). Dependency-ready after handoff: #181 (product · outcome hubs), then #189 (content · fresh reporting). #183 remains deferred scheduling backlog. Next eligible action is independent review of #187; pause state: none.

13. Cycle 86 · October 2, 2026Exact-head review

    Fresh reporting on aging biomarkers and their limits

    Issue #185 / PR #188 adds two substantive reports only after a bounded freshness checkpoint, three frozen research passes, claim-level evidence review and a release-time source/status recheck.

    • Reports the September 7 rentosertib proteomic-clock analysis while keeping its 42-person IPF ancillary subset, short phase 2a parent trial, company involvement and clock-versus-clinical-outcome boundaries explicit.
    • Reports the September 21 CT biological-age paper while preserving Article-in-Press status, the single-center 7,837-person cohort, relative associations, small discrimination increment, radiation context and lack of external validation.
    • Projects both stories into the canonical 57-story manifest, Home, Latest, Measuring aging, Topics, Research, Evidence, covered approaches, two governed Study records, NCT05938920, the 253-record private Search and sitemaps; adds distinct publication-owned graphics and non-evidence captions.
    • Verification state: the October 2 source/registry/regulator/funding/availability recheck found no claim-changing update. Growth passes at the current review series. Quality attempts through #797 exposed bounded projection-count, structured-data and search-render contracts; #798 passed repository, container and smoke gates, then stopped on stale responsive counts and the two new article-format assertions. #800 cleared those assertions and exposed one obsolete Cycle 63 compatibility exception. #802 retired it and reached the next governed visual suite, which exposed stale intervention-directory, Research and Search totals; those assertions and their superseded compatibility exceptions are now reconciled. Downstream trial, study and private-Search visual totals were also brought forward to 61, 135 and 253. #810 then isolated one final stale Research route-card total (43→44), now reconciled. No scientific prose changed during refinement. Exact-head hosted 1280/390/320 rendering, accessibility, manual screenshot review, deployment and production verification remain pending.

    Priority queue: active #185 aging-biomarker reporting; then #187 absolute/relative-risk explainer (content); then #181 outcome hubs (product). #183 remains deferred scheduling backlog. Adoption-forward ledger: 0 normal, 0 content, 0 product; #185 earns no credit before merge, deployment and production verification.

14. Cycle 85 · October 1, 2026Review pending

    Living evidence for testosterone, GLP-1 drugs and calorie restriction

    Issue #178 / PR #184 extends the governed living-page system to three exact canonical intervention identities without adding a source, medical claim or recommendation.

    • Projects five released stories, twelve covered study/source records and four exact clinical-trial records from the existing governed datasets.
    • Keeps testosterone cardiovascular, fracture and physical-function outcomes separate; keeps SELECT’s molecule, dose and enrolled population distinct from broad GLP-1 or anti-aging claims; keeps CALERIE’s supported two-year protocol distinct from lifespan and unsupervised restriction.
    • Adds a descriptive three-page comparison whose counts and order are not evidence strength, efficacy, safety, importance, popularity or recommendation.
    • Verification state: deterministic projection and integration checks are prepared; exact-head repository, container, hosted responsive, accessibility, manual review, deployment and production gates remain pending.

    Ready queue: #181 outcome hubs for heart, cognition and independence; #183 corrected evidence record index.

15. Cycle 84 · October 1, 2026Production verified

    A filterable library of governed claims

    Issue #176 / PR #182 shipped the exact 42 already released claim records as one static-first reader index.

    • Keeps topic, article, relationship, evidence role, population, comparator, outcome, maturity, result, boundary, limitations, funding/conflicts, correction state, verification date and exact source identities attached to every claim.
    • Adds local free-text and structured filters with canonical shareable state, honest no-match recovery, browser history and a complete no-JavaScript library.
    • Omits analytics loaders and remote requests so query text stays in the reader’s browser; adds no claim, score, recommendation, semantic inference or personalized guidance.
    • Verification state: exact-head Growth #314 and Quality #737 passed; hosted 1280px, 390px and 320px evidence was manually reviewed; Deploy #92 and changed-route production verification passed on Cloud Run revision moreyears-news-00095-lpv.

    Ready queue at release: #178 living evidence pages for testosterone, GLP-1 drugs and calorie restriction; #181 outcome hubs for heart, cognition and independence; #183 corrected evidence record index.

16. Cycle 83 · October 1, 2026Production verified

    Side-by-side comparison for covered clinical trials

    Issue #174 shipped through PR #179; production then exposed one plural-agreement defect in the filter-hidden selection notice. PR #180 repaired and re-verified the release.

    • The released comparison remains operational for two or three exact registry records, shareable canonical URLs, filters, removal, clearing, copy-link status and browser history.
    • The repair preserves singular “remains” and uses plural “remain,” with direct zero/singular/plural assertions and an exact hosted responsive assertion for two hidden selected trials.
    • No registry fact, released story, medical claim, comparison field, URL behavior, analytics, persistence, remote request or architecture changes.
    • Verification state: exact-head Quality #731, Deploy #91, hosted responsive review and production checks passed on Cloud Run revision moreyears-news-00094-f47.

    Ready queue at release: #176 governed claims library; #178 living evidence pages for testosterone, GLP-1 drugs and calorie restriction; #181 outcome hubs.

17. Cycle 82 · October 1, 2026Production verified

    Living evidence pages for aspirin, sleep and vitamin D

    Issue #172 / PR #177 extended the governed living-page system to three exact canonical intervention identities without adding a medical claim or changing a released conclusion.

    • Projects three low-dose-aspirin stories, one sleep story and one vitamin D story with their exact covered publications, trial records and governed evidence boundaries.
    • Keeps disability-free survival, cardiovascular outcomes, cancer follow-up, major bleeding, sleep duration, regularity, fragmentation, deficiency treatment and broad prevention visibly distinct.
    • Adds an explicit no-covered-trial state for sleep and descriptive three-page comparisons whose counts and order are not evidence strength, efficacy, safety, importance, popularity or recommendation.
    • Exact-head Growth #297 and Quality #717 passed; responsive review, deployment and all changed production-route checks passed at release bb4fcbd2618d6755bb66ea7236f4c8bb812ab249.

    Ready queue at release: #174 compare covered clinical trials; #176 governed claims library.

18. Cycle 81 · September 30, 2026Production verified

    Real claim–evidence maps for three released coverage bundles

    Issue #170 / PR #175 published indexable, static-first maps for cancer screening, metabolic health, and falls and independence from the exact governed claim maps behind nine released analyses.

    • Projects all 42 governed claims with stable IDs, population or model, comparator, outcome, design maturity, result, boundary, limitations, funding/conflicts, correction state, and exact source links.
    • Keeps direct support, contradiction, indirect context, and insufficient evidence visibly distinct without scores, rankings, treatment recommendations, or new medical claims.
    • Exact-head Growth #287 and Quality #706 passed, including a manually inspected 51-capture artifact at 1280px, 390px and 320px.
    • PR #175 merged as 0981114ec59b120525479531d1f1d09b98324489; production verification passed the three claim-map routes, Research, Search, nine connected stories, sitemap, Development, GA4 assets and the custom 404.

    Ready queue at release: #172 expand living evidence pages; #174 compare covered clinical trials.

19. Cycle 80 · September 30, 2026Production verified

    Side-by-side comparison for covered studies

    Issue #168 through PR #173 adds accessible selection for all 133 canonical study records, a deterministic two- or three-study URL state, exact source-field matrices on desktop, stacked comparison cards on mobile, removal, clearing and link copying. It preserves the complete no-JavaScript directory and adds no storage, telemetry, evidence ranking, inferred relationship or medical claim. Deterministic, accessibility, responsive, deployment, and changed-route production checks passed on September 30, 2026.

    Ready queue at release: #170 real claim-evidence maps; #172 expand living evidence pages; #174 compare covered clinical trials.

20. Cycle 79 · September 30, 2026Production verified

    Living evidence pages for exercise, metformin and rapamycin

    Issue #167 / PR #171 published three generated, source-bound pages connecting released reporting to exact covered-study and clinical-trial identities without adding medical claims, rankings or inferred relationships. Exact-head CI, responsive review, deployment and changed-route checks passed on Cloud Run revision moreyears-news-00089-tfj at merge 4f78a5e042397ab019ef6c9e41bbda252daa620e.

21. Cycle 78 · September 30, 2026Production verified

    Cross-record search across released evidence

    Issue #166 / PR #169 expanded private local Search across 55 stories, 133 studies/publications and 60 clinical-trial registry identities. Exact-head Quality #679, responsive review, deployment and all changed-route checks passed on Cloud Run revision moreyears-news-00088-slr at merge 289c91b3c876a96af4b53fafb4a8fb5e0e73c0f0.

22. Cycle 77 · September 30, 2026Production verified

    Privacy-preserving search across released evidence

    Issue #159 / PR #165 launched private local Search across all 55 released stories. Exact-head Growth and Quality, 47 manually inspected responsive captures, deployment, all 115 changed routes, analytics exclusion, metadata, sitemap, GA4 preservation and custom 404 passed on Cloud Run revision moreyears-news-00087-w5p.

23. Cycle 76 · August 28, 2026 Production verified

    Making the evergreen longevity foundations guide unmistakable on Home

    Issue #162 / PR #164 published the prominent Home feature. Exact-head CI, hosted responsive review, deployment and changed-route production checks passed on Cloud Run revision moreyears-news-00086-f9b.

24. Cycle 75 · August 27, 2026 Production verified

    Covered studies from released evidence

    Issue #152 / PR #161 published 133 deduplicated primary publications and governing syntheses connected to all 55 released stories. Exact-head CI, hosted responsive review, deployment and changed-route production checks passed on Cloud Run revision moreyears-news-00085-6s6.

25. Cycle 74 · August 27, 2026Production verified

    Covered clinical trials from released evidence

    Issue #148 / PR #160 published 60 deduplicated registry records connected to 45 of 55 released stories. CI, responsive inspection, deployment, all changed production routes, GA4 and the custom 404 passed.

26. Cycle 73 · August 27, 2026Production verified

    10 things you can do for a longer, healthier life

    Issue #155 / PR #158 published the unranked evidence-first guide and its source-reviewed smoking-cessation mortality analysis. CI, responsive inspection, deployment and all changed production routes passed.

27. Cycle 72 · August 26, 2026Production verified

    Discovery inventories repaired after the 54-story release

    Issue #156 / PR #157 reconciled Latest, the Evidence Tracker, Research and the covered-interventions directory. Production passed at 54 stories and 49 approaches.

28. Cycle 71 · August 26, 2026 · pre-deployment handoffReview pending

    Falls and independence: STRIDE, LiFE and tailored Tai Ji Quan

    Issue #144 is implemented on its governed branch; review continues in PR #154, which supersedes PR #153 at the same reviewed branch head after GitHub failed to register exact-head checks.

    • Three research passes and 12 atomic claims were frozen before drafting.
    • Three source-reviewed articles preserve distinct populations, comparators, fall outcomes, limits, funding/conflicts and safety context.
    • Canonical projections now describe 54 stories, 21 Health & function stories and 49 covered approaches.
    • Review refinement aligned category totals, recirculation, semantic dates, rendered illustration counts and the Cycle 71 responsive contract; it also added visible byline separation and article-specific failure-state evidence. A fresh exact-head CI rerun, complete responsive visual review, deployment and production verification remain pending.
29. Cycle 70 · August 26, 2026Production verified

    Cycle 69 homepage discovery repaired

    Production verification of issue #142 found its three metabolic-health analyses live across Latest, Topics and the evidence directories but absent from Home’s six-story grid. Repair issue #150 / PR #151 restored DPP/DPPOS, Look AHEAD and ACCORD to Home in newest-first order, retained exactly six cards and corrected the Home evidence-tracker count to 51. The bounded repair was merged, deployed and production-verified before normal roadmap work resumed.

30. Cycle 69 · August 26, 2026Production verified after bounded repair

    Metabolic-health trials edition

    Issue #142 / PR #149 published DPP/DPPOS, Look AHEAD and ACCORD analyses. Production verification found their Home discovery cards missing; issue #150 / PR #151 completed the bounded Cycle 70 repair.

31. Cycle 68 · August 25, 2026 · started 11:24 p.m. CDTRelease repair in review

    Repairing the Cycle 67 Development queue snapshot

    This bounded production repair addresses issue #146 through PR #147.

    • Production verification found the Q3 report and all reader integrations live, but this page's ready-queue block still described completed Cycle 65 work.
    • Replaces #123/#140 and the obsolete #138 review state with the exact untouched dependency-ready queue: #142, then #144.
    • Adds deterministic assertions that reject completed, merged or actively repairing issues from the ready-queue cards.
    • Leaves all 48 stories, the Q3 report and snapshot, medical content, analytics, routes, sitemap and reader integrations unchanged.
    • Verification state: the production defect is reproduced and the bounded fix is prepared; exact-head CI, container, hosted responsive screenshots, accessibility, manual review, deployment and full Cycle 67 production re-verification remain pending.
32. Cycle 67 · August 25, 2026 · started 8:51 p.m. CDTRelease repair required

    Publishing a quarterly State of Human Longevity Evidence report

    This reader-understanding increment addresses issue #140 through PR #145.

    • Freezes a versioned 2026 Q3 snapshot from the canonical 48-story tracker and published-coverage manifests.
    • Counts primary outcome, evidence design, topic, population, publication format and 83 explicitly overlapping measured-result assignments without converting frequency into an evidence score.
    • Adds accessible tables, text equivalents, methodology, coverage limits and a distinct 1,600 × 900 publication-owned chart.
    • Connects the report from Home, Research, Learn and the evidence tracker; #142 and #144 remain dependency-ready and untouched.
    • Verification state: exact-head Quality #519, Growth #78, artifact-digest checks and responsive manual review passed; PR #145 deployed the report and reader integrations, but production verification found this page's ready-queue block still described completed Cycle 65 work. Issue #146 is the bounded release repair, and issue #140 remains incomplete until it deploys.
33. Cycle 66 · August 25, 2026 · started 6:51 p.m. CDTProduction verified

    Giving the heat, cold and HBOT evidence edition distinct visual identities

    This reader-comprehension increment addresses issue #123 through PR #143.

    • Adds three distinct publication-owned originals for the sauna, cold-water and hyperbaric-oxygen stories without adding or strengthening any scientific claim.
    • Keeps observational heat exposure, selected short-term physiology and isolated blood-cell biomarkers visually separate from causal, clinical, healthspan or lifespan outcomes.
    • Extends the canonical nine-asset illustration manifest, responsive AVIF/WebP/JPEG formats, article discovery metadata, Home/Latest/Topics/category cards and evidence-before-art article figures.
    • Leaves #140 and #142 dependency-ready; no other implementation is active.
    • Verification state: Quality #509, exact-head deterministic, production-container, hosted responsive, accessibility, manual screenshot, deployment and production checks passed on August 25, 2026.
34. Cycle 65 · August 25, 2026 · started 3:00 p.m. CDTProduction verified

    Turning released intervention coverage into a reader directory

    This reader-discovery increment addresses issue #138 through PR #141.

    • Projects 48 released evidence rows into 43 canonical intervention or exposure records without inferring from headlines or general knowledge.
    • Keeps population, evidence design, measured outcome, released bottom line, explicit not-shown boundary and verification date attached to every linked story.
    • Adds shareable category and evidence-design filters, honest no-match recovery, browser-history support and complete no-JavaScript output.
    • Integrates the reader directory from Interventions, Research and Learn while keeping the fixture preview secondary; #123 and #140 remain ready and untouched.
    • Verification state: Quality #498, exact-head deterministic, production-container, hosted responsive, accessibility, manual screenshot, deployment and production checks passed on August 25, 2026.
35. Cycle 64 · August 25, 2026 · started 5:50 a.m. CDTProduction verified

    Turning 48 released stories into a filterable human-longevity evidence tracker

    This reader-discovery increment addresses issue #135.

    • Evolves Evidence at a glance in place so every canonical released story appears exactly once across five primary outcome groups.
    • Adds shareable progressive filters for outcome, evidence design, population or model, topic category and measured result while preserving all stories without JavaScript.
    • Keeps population, design, measured outcomes, released bottom line, explicit boundary and verification date together; it adds no ranking, score, recommendation or new medical claim.
    • Connects the tracker from Home, Learn, Research, Interventions, Aging Biology and Start Here; #138 and #123 remain dependency-ready.
    • Verification state: Quality #485, exact-head deterministic, container, hosted responsive, accessibility, manual screenshot, deployment and production checks passed on August 25, 2026.
36. Cycle 63 · August 24, 2026 · started 7:26 a.m. MDTProduction verified

    Putting cancer-screening benefits and harms in the same frame

    This source-reviewed content increment addresses issue #127 through PR #136.

    • Completes three separated evidence-review passes, then freezes 18 atomic claims across NordICC colonoscopy, NLST low-dose CT and Rotterdam ERSPC PSA screening.
    • Publishes three reader-facing analyses that keep invitation versus participation, selected eligibility, cancer-specific mortality, false positives, overdiagnosis and all-cause survival separate.
    • Raises the library from 45 to 48 stories and integrates the edition across Home, Latest, Topics, the 17-story Health & function hub, Research, Interventions, Aging Biology, Evidence at a glance and the canonical/news sitemaps.
    • Adds three distinct 1,200-pixel publication-owned graphics and preserves Lois Rune, publisher, article image, AI-disclosure and sitewide GA4 metadata.
    • Verification state: the original release and bounded Interventions-count repair passed exact-head CI, responsive review, deployment and production checks on August 24, 2026.
37. Cycle 61 · August 5, 2026 · started 5:53 a.m. MDTReview pending

    Preparing the publication for search, authority and audience growth

    This manually directed launch-readiness increment addresses issue #129.

    • Limits canonical and news sitemaps to genuine reporting and public reader destinations while marking preview, workflow, development and demonstration routes noindex,follow.
    • Adds Lois Rune as the visible and structured author of all 45 stories, publishes her author profile and AI-assistance disclosure, and completes publisher and image metadata.
    • Gives every story a relevant publication-owned image at least 1,200 pixels wide, preserving evidence-safe artwork and scientific boundaries.
    • Adds privacy-conscious analytics hooks, newsletter launch-list capture, accurate modification dates, a two-day news sitemap and deterministic launch-readiness validation.
    • Verification state: complete local deterministic validation passes. Exact-head container, hosted responsive, screenshot, deployment, production and Search Console submission checks remain pending.
38. Cycle 60 · August 4, 2026 · started 8:51 a.m. MDTProduction verified

    Testing emerging supplement claims against human outcomes

    This source-reviewed content increment addresses issue #121 through PR #128.

    • Completes three separated evidence-review passes before prose, then freezes 18 atomic claims and 18 scoped assessments for spermidine, urolithin A and GlyNAC.
    • Adds three reader-facing stories that lead with null primary outcomes, small samples, endpoint hierarchy and product-specific limits—not supplement marketing.
    • Raises the library from 42 to 45 stories and integrates the edition across Home, Latest, Topics, the 17-story Drugs & supplements hub, Interventions, Aging Biology, Research, Start Here, Evidence at a glance, sitemap and recirculation.
    • Verification state: Quality #447, exact-head deterministic, production-container, HTTP/custom-404, hosted responsive, accessibility, manual 1280/390/320 screenshot review, deployment and production checks passed; the release was verified on August 5, 2026.
39. Cycle 59 · August 4, 2026 · started 6:52 a.m. MDTProduction verified

    Turning site language into reasons to read

    This reader-comprehension increment addresses issue #125 through PR #126.

    • Replaces generic process and system headings with concrete questions, findings and reader benefits across Home, Latest, Topics, Start Here, Interventions, Aging Biology, Research, Learn and four category hubs.
    • Gives all 42 released articles topic-specific related-reading and recirculation titles instead of “Continue through the knowledge system” and “Keep reading.”
    • Preserves canonical story headlines, medical and scientific claims, citations, evidence scope, navigation targets, metadata, ordering and the 42-story manifest.
    • Adds deterministic rejection of the retired phrases plus hosted desktop, mobile and narrow evidence across every changed route; exact-head CI, screenshot review, deployment and production verification passed at 8:20 a.m. MDT on August 4, 2026.
40. Cycle 58 · August 4, 2026 · started 1:55 a.m. MDTProduction verified

    Making the complete story archive easier to narrow

    This reader-discovery increment addresses issue #119 through PR #124.

    • Adds topic, measured-outcome and evidence-design controls across all 42 released stories while preserving newest-first order and every canonical card.
    • Uses a versioned projection derived from released metadata, AND-between-dimensions filtering, exact result counts, shareable query parameters, safe normalization, a clear-all action and an honest no-match recovery path.
    • Preserves progressive enhancement: without JavaScript, every story remains visible and readable.
    • Verification state: Quality #426, deterministic, container, hosted responsive, accessibility, manual 1280/390/320 screenshot review, deployment and production checks passed; the release was verified at 6:12 a.m. MDT on August 4, 2026.
41. Cycle 57 · August 3, 2026 · started 8:52 p.m. MDTProduction verified

    Separating heat, cold and hyperbaric-oxygen signals from longevity claims

    This source-reviewed content increment addresses issue #117 through PR #122.

    • Prepares three reader-facing stories on sauna and mortality associations, cold-water thermogenesis, and hyperbaric-oxygen blood-cell biomarkers.
    • Separates observational association from causation; physiology and biomarker changes from clinical outcomes; and selected cell measurements from whole-body aging, healthspan or lifespan.
    • Commits two dated research passes before prose, verified primary identifiers, counterevidence, funding and conflicts, current CDC/FDA safety context, 18 atomic claims and 18 evidence assessments.
    • Raises the candidate library from 39 to 42 stories, publishes a Measuring aging category hub, and expands Evidence at a glance from 18 to 21 outcome comparisons.
    • Verification state: exact-head deterministic, production-container, hosted responsive, accessibility, manual 1280/390/320 screenshot review, deployment and changed-route production checks passed; the release was verified at 1:33 a.m. MDT on August 4, 2026.
42. Cycle 56 · August 3, 2026 · started 6:56 p.m. MDTProduction verified

    Expanding Start Here with outcome-led reading paths

    This reader-discovery increment addresses issue #115 through PR #120.

    • Adds heart and circulation, brain and cognition, and strength, bones and independence paths alongside the four released orientation paths.
    • Uses only already reviewed coverage and keeps cardiovascular events, mortality, prevention setting, cognitive tests, dementia outcomes, subgroup findings, bone density, fractures, mobility and physical function visibly distinct.
    • Connects the seven-path experience from Home, Latest and relevant category hubs without displacing newest or complete-story discovery.
    • Verification state: Quality #394, exact-head deterministic, production-container, hosted responsive, accessibility, manual 1280/390/320 screenshot review, deployment and changed-route production checks passed; the release was verified at 8:09 p.m. MDT on August 3, 2026.
43. Cycle 55 · August 3, 2026 · started 3:52 p.m. MDTProduction verified

    Preparing an ASPREE aspirin and healthy-aging evidence edition

    This source-reviewed content increment addresses issue #113 through PR #118.

    • Prepares bounded reporting on disability-free survival, cardiovascular events versus major bleeding, and mortality/cancer outcomes across ASPREE and ASPREE-XT.
    • Separates primary from secondary prevention; composite outcomes from components; cancer incidence from cancer mortality; and randomized treatment from post-trial observational follow-up.
    • Commits two dated research passes before prose, 9 verified sources, 21 atomic claims and 21 evidence assessments, plus current FDA and USPSTF context.
    • Raises the candidate library from 36 to 39 stories and integrates all three across Home, Latest, Topics, Drugs & supplements, Interventions, Aging Biology, Research, Learn, Evidence at a glance, sitemap and recirculation.
    • Verification state: Quality #388, exact-head deterministic, production-container, hosted responsive, accessibility, manual 1280/390/320 screenshot review, deployment and changed-route production checks passed; the release was verified at 6:15 p.m. MDT on August 3, 2026.
44. Cycle 54 · August 3, 2026 · started 1:52 p.m. MDTProduction verified

    Expanded evidence-safe illustrations to the sleep edition

    This reader-discovery increment addresses issue #111; released through PR #116.

    • Adds three distinct publication-owned illustrations to the CBT-I, CPAP and melatonin stories without changing a medical claim, source, category, title, deck, evidence scope, story order or the 36-story count.
    • Reuses each canonical asset on its article plus Home, Latest, Topics and the relevant category hub, while keeping evidence boxes ahead of artwork and labeling every article image as editorial illustration—not evidence.
    • Extends the versioned manifest to six assets, records creation and rights provenance, preserves responsive AVIF/WebP/JPEG formats, intrinsic dimensions and below-fold lazy loading, and adds 16 deterministic rejection fixtures.
    • Verification state: Quality #361, exact-head repository, production-container, hosted responsive, accessibility, deployment and production checks passed; the release was verified at 3:31 p.m. MDT on August 3, 2026.
45. Cycle 53 · August 3, 2026 · started 10:53 a.m. MDTProduction verified

    Published a men’s healthy-aging testosterone evidence edition

    This source-reviewed content release addresses issue #109 through PR #114.

    • Published bounded reporting on TRAVERSE cardiovascular noninferiority, TRAVERSE fracture outcomes, and Testosterone Trials physical-function results.
    • Preserved indication, formulation, population, primary-versus-secondary outcome, noninferiority, bone-density surrogate, clinical fracture, safety, regulatory, anti-aging, healthspan and lifespan boundaries in 22 atomic claims.
    • Raised the canonical library from 33 to 36 stories and integrated the edition across reader discovery, categories, evidence records and recirculation.
    • Verification state: exact-head repository, editorial, container, responsive visual, accessibility, deployment and changed-route production checks passed at 1:16 p.m. MDT on August 3, 2026.
46. Cycle 52 · August 3, 2026 · started 4:53 a.m. MDTProduction verified

    Creating an outcome-first evidence comparison guide

    This reader-discovery increment addresses issue #107 through PR #112.

    • Adds an indexable Evidence at a glance guide covering 15 source-reviewed stories in five outcome groups.
    • Keeps intervention, population or model, study design, measured outcome, released bottom line, evidence scope, verification date, and explicit boundary together.
    • Uses canonical released metadata only; it adds no evidence score, ranking, recommendation, or new medical claim.
    • Integrates the guide into Home, Learn, Interventions, Aging Biology, Research, sitemap, container smoke checks, and hosted responsive QA.
    • Verification state: full CI and manual review of 53 responsive screenshots passed; all integrations, story links, metadata, the custom 404, deployment, and production checks passed at 9:59 a.m. MDT on August 3, 2026.
47. Cycle 51 · August 2, 2026 · started 9:53 p.m. MDTProduction verified

    Publishing a sleep and circadian-health evidence edition

    This source-reviewed content increment addresses issue #105 through PR #110.

    • Adds bounded reporting on CBT-I for later-life insomnia, SAVE and ISAACC CPAP cardiovascular outcomes, and product-specific melatonin sleep evidence.
    • Preserves sleep, symptom, cardiovascular, safety, regulatory, biological-aging, healthspan and lifespan boundaries in 15 atomic claims.
    • Documents three separated research passes, verified primary identifiers, counterevidence, absolute outcomes, funding/conflicts and ten deterministic mutation rejections.
    • Raises the canonical library from 30 to 33 stories and integrates the edition across Home, Latest, Topics, three category hubs, Interventions, Aging Biology, Research, Learn, sitemap and recirculation.
    • Verification state: Quality #352, responsive visual inspection, accessibility, production-container, HTTP/custom-404, deployment, and production checks passed; the release was verified at 4:06 a.m. MDT on August 3, 2026.
48. Cycle 50 · August 2, 2026 · started 4:53 p.m. MDTProduction verified

    Publishing an immune-aging and adult-vaccination evidence edition

    This source-reviewed content increment addresses issue #103 through PR #108.

    • Adds bounded reporting on shingles vaccination and non-randomized dementia findings, high-dose influenza vaccination in older adults, and product-specific RSV vaccine trials.
    • Preserves vaccine product, study design, population, endpoint, absolute-versus-relative effect, immunogenicity, guidance, safety, mortality, healthspan and lifespan boundaries in 19 atomic claims.
    • Documents three research passes before prose, verified primary identifiers and current public-health/regulatory sources, funding/conflicts, 13 rejection fixtures, and standing publication authorization.
    • Raises the canonical library from 27 to 30 stories and integrates the edition across Home, Latest, Topics, Health & function, Interventions, Aging Biology, Research, Learn, sitemap, recirculation and hosted responsive QA.
    • Verification state: the complete exact-head CI, production-container, HTTP/custom-404, responsive visual, accessibility, deployment, and production checks passed; the release was verified at 9:13 p.m. MDT on August 2, 2026.
49. Cycle 49 · August 2, 2026 · started 3:53 p.m. MDTProduction verified

    Adding an evidence-safe editorial illustration pilot

    This reader-discovery increment addresses issue #101 through PR #106.

    • Adds three publication-owned originals for FINGER, MIND, and ACTIVE, with responsive AVIF/WebP variants and JPEG fallbacks.
    • Reuses each visual on its article, Home, Latest, Topics, and relevant category hub while preserving the 27-story order, counts, claims, sources, evidence boxes, and recirculation.
    • Captions identify editorial illustration—not a measured result or scientific evidence—and the manifest records identity, provenance, rights, status, alt, credit, dimensions, formats, loading, dates, and non-evidence boundaries.
    • Adds manifest/render validation, eleven rejection fixtures, and hosted image-loading, intrinsic-size, responsive, accessibility, console, clipping, and overflow checks.
    • Verification state: Quality #324, responsive visual inspection, accessibility, production-container, deployment, and production checks passed; the release was verified at 4:41 p.m. MDT on August 2, 2026.
50. Cycle 48 · August 2, 2026 · started 10:51 a.m. MDT Production verified

    Preparing three women’s healthy-aging evidence stories

    This source-reviewed content increment addresses issue #97 through PR #104.

    • Adds bounded reporting on menopausal hormone therapy and WHI, zoledronic-acid fracture prevention in HORIZON, and the small supervised LIFTMOR resistance-training trial.
    • Preserves formulation, uterus status, symptom, disease, BMD, fracture, function, safety, mortality, healthspan, lifespan, funding, and correction boundaries in 21 atomic claims.
    • Documents three research passes before prose, a versioned evidence bundle, 15 rejection fixtures, 27-story discovery integration, and responsive hosted-QA coverage.
    • Review refinements aligned four stale Cycle 47/site-inventory assertions, then corrected two category-hub count attributes that still exposed the prior 24-story manifest values.
    • Verification state: Quality #320, responsive visual inspection, accessibility, deployment, and production checks passed; the release was verified at 3:08 p.m. MDT on August 2, 2026.
51. Cycle 47 · August 2, 2026 · started 8:54 a.m. MDT Production verified

    Created a guided Start Here path through published coverage

    This reader-discovery increment addresses issue #95 through PR #102.

    • Adds four short paths for readers new to longevity science, everyday-life questions, drugs and supplements, and experimental science or aging measurements.
    • Connects already-released guides, topic hubs, and source-reviewed stories with an explicit reason, format, and evidence scope for every ordered step plus a clear archive or category exit.
    • Places the guide after stories and topic discovery on Home and connects it from Learn without removing or demoting the eight existing research-literacy guides.
    • Adds a versioned reading-path map, sequence-not-ranking and medical-advice boundaries, eleven rejection fixtures, sitemap and container coverage, and hosted desktop/mobile/narrow review; #97 and #101 remain dependency ready.
52. Cycle 46 · August 2, 2026 · started 7:54 a.m. MDT Production verified

    Repaired the stale story total on Latest

    This bounded release repair addresses issue #99 through PR #100.

    • Corrects the current Latest introduction from twenty-one to twenty-four source-reviewed articles so it agrees with the released manifest, header status, machine-readable count, and 24 rendered archive cards.
    • Adds a manifest-derived written-count check and strengthens the visible-count rejection fixture so future story editions cannot leave the reader-facing archive prose behind.
    • Preserves article copy, medical claims, sources, categories, recirculation, navigation, and historical Development counts; #95 and #97 remain the dependency-ready queue.
53. Cycle 45 · August 2, 2026 · started 4:53 a.m. MDT Production verified

    Published three source-reviewed cognitive-aging stories

    This release addresses issue #93 through PR #98.

    • Publishes bounded reporting on the FINGER multidomain program, the randomized MIND diet trial, and ACTIVE cognitive training, raising the real-story library from twenty-one to twenty-four.
    • Keeps cognitive-test performance, MRI measures, daily function, claims-diagnosed dementia, adverse events, mortality, healthspan, and lifespan as separate outcomes rather than one “brain health” verdict.
    • Preserves three research passes, fourteen verified source records, nine study records, three trial records, fifteen atomic claims, fifteen evidence assessments, funding/conflict context, correction state, and the published ACTIVE critique-and-response dispute.
    • Integrates the stories into Home, Latest, Topics, category hubs, Interventions, Aging Biology, Research, Learn, sitemap, recirculation, container routes, and hosted desktop/mobile/narrow QA; exact-head review, deployment, and production verification passed.
54. Cycle 44 · August 2, 2026 · started 1:54 a.m. MDT Production verified

    Made a real evergreen explainer visual, scannable, and media-ready

    This release candidate addresses issue #91 through PR #96.

    • Adds a category/content/evidence context row, claim-linked takeaways, a know/do-not-know boundary, an outcome-specific evidence matrix, and a semantic population → outcome → limit figure to the source-reviewed exercise explainer.
    • Preserves the existing scientific body, evidence box, sources, disclosures, history, and next reads while mapping every new summary to the canonical four exercise claims and five sources.
    • Defines and validates provider-independent draft states for video, full narration, and short audio summaries, with separate scientific, editorial, accessibility, provenance, transcript, human-approval, publication, correction, withdrawal, regeneration, and supersession gates.
    • Publishes no media, provider connection, player, download, “coming soon” promise, ranking, recommendation, or new medical claim; exact-head deterministic, container, responsive, accessibility, console, and visual review remain required.
55. Cycle 43 · August 1, 2026 · started 11:53 p.m. MDT Production verified

    Created reader-first category hubs for published coverage

    This release candidate addresses issue #89 through PR #94.

    • Adds dedicated Everyday foundations, Drugs & supplements, and Health & function hubs with a reader question, newest coverage, complete manifest-derived story list, evidence scope, and direct paths to Topics and Latest.
    • Links eligible Topics headings and story counts to the hubs while keeping the two single-story categories honestly on the index, without padded destinations or fixture/process material.
    • Adds a versioned category projection, six rejection fixtures, deterministic route/count/order/metadata agreement, sitemap and production-route coverage, and hosted desktop/mobile/narrow capture.
56. Cycle 42 · August 1, 2026 · started 9:53 p.m. MDT Production verified

    Connected every published story to useful next reads

    This release candidate addresses issue #85 through PR #92.

    • Adds three transparent next reads to each of twenty-one source-reviewed stories, with a plain-language relationship reason, format, category, evidence scope, and editorial boundary.
    • Stores sixty-three current relationships in a versioned map with independent provenance, editorial, correction, and history state; deterministic checks reject self-links, duplicates, dangling or fixture targets, stale records, and page-to-data disagreement.
    • Makes each Topics category expose its exact story count, newest coverage, and path to the complete Latest archive, with shared responsive styling and hosted Chromium QA.
57. Cycle 41 · August 1, 2026 · started 5:52 p.m. MDT Production verified

    Prepared a seventh edition of sourced longevity coverage

    This release candidate addresses issue #81 through PR #90.

    • Prepares a VITAL vitamin D claim check, a COSMOS multivitamin research analysis, and a resveratrol evidence explainer that separates mechanisms, biomarkers, disease outcomes, cognition, function, safety, healthspan, and lifespan.
    • Records three separate research passes, verified primary and registry identifiers, funding and product provision, corrections, explicit population and formulation boundaries, claim-scoped evidence roles, and twelve deterministic rejection fixtures.
    • Raises the real-story library from eighteen to twenty-one and connects the edition to Home, Latest, Topics, Interventions, Aging Biology, Research, Learn, sitemap, container routes, and hosted responsive QA.
58. Cycle 40 · August 1, 2026 · started 3:54 p.m. MDT Production verified

    Repairing stale published-story counters

    This bounded release repair addresses issue #87 through PR #88.

    • Production verification after the sixth-edition deployment found that the three new stories and all eighteen links were live, while Home, Latest, and Topics still announced a fifteen-story library.
    • Corrects the visible counters to eighteen and makes deterministic validation compare Home, Latest, and Topics count labels with the canonical published-coverage manifest.
    • Leaves article prose, sources, categories, navigation, and the ready #81/#85 queue unchanged.
59. Cycle 39 · August 1, 2026 · started 2:53 p.m. MDT Production verified after Cycle 40 repair

    Prepared a sixth edition of sourced longevity coverage

    This release candidate addresses issue #79 through PR #86.

    • Prepares a SPRINT analysis that separates cardiovascular, mortality, cognition, safety, and population limits; a statin explainer that distinguishes secondary from late-life primary prevention; and an omega-3 claim check that keeps formulations, populations, comparators, and outcomes distinct.
    • Records three separate research passes, 18 canonical sources, 11 studies, seven trials, nine atomic claims, absolute outcomes, correction and registry checks, funding and conflicts, safety context, and explicit non-longevity boundaries.
    • Raises the real-story library from fifteen to eighteen and connects all three stories to Home, Latest, Topics, Interventions, Aging Biology, Research, Learn, sitemap, deterministic validation, container routes, and hosted responsive QA.
    • Post-deployment verification found that Home, Latest, and Topics still displayed fifteen-story counters; Cycle 40 records the bounded repair before issue #79 can be completed.
60. Cycle 38 · August 1, 2026 · started 7:51 a.m. MDT Production verified

    Put published stories first

    This release candidate addresses issue #83 through PR #84.

    • Reorders Home around a real featured story, six recent stories, and five plain-language topic categories before reader education and process links.
    • Makes Latest the complete newest-first archive and populates Topics with all fifteen sourced stories, category counts, evidence scope, and direct reading paths.
    • Reduces primary navigation to five reader destinations and adds a versioned coverage manifest with deterministic disagreement and rejection fixtures.
61. Cycle 37 · August 1, 2026 · started 1:52 a.m. MDT Production verified

    Prepared a fifth edition of sourced longevity coverage

    This release candidate addresses issue #77 through PR #82.

    • Prepares an ACHIEVE hearing-and-cognition analysis led by the null overall result, a time-restricted-eating explainer with comparator-specific findings and both TREAT corrections, and a creatine brief that separates training outcomes from longevity.
    • Records three separate research passes, 16 canonical sources, nine atomic claims, correction history, subgroup limits, conflicts and funding, safety and regulatory context, and an explicit unavailable creatine disclosure field.
    • Connects all three stories to Latest, the homepage, category hubs, topics, guides, sitemap, deterministic validation, container route tests, and hosted responsive screenshot review.
62. Cycle 36 · July 31, 2026 · started 10:54 p.m. MDT Production verified

    Prepared a fourth edition of sourced longevity coverage

    This release candidate addresses issue #75 through PR #80.

    • Publishes a functional-outcome explainer on physical activity and late-life mobility, a SELECT analysis that separates cardiovascular benefit from anti-aging claims, and a claim check on NAD precursor supplements.
    • Records three separate research passes, primary identifiers, correction checks, negative findings, sponsor and product-supply disclosures, current regulatory context, and claim-by-claim evidence boundaries.
    • Connects all three stories to Latest, the homepage, category hubs, topics, guides, sitemap, deterministic validation, container smoke tests, and hosted responsive screenshot review.
63. Cycle 35 · July 31, 2026 · started 6:54 p.m. MDT Production verified

    Prepared a third edition of sourced longevity coverage

    This release candidate addresses issue #73 through PR #78.

    • Publishes an evidence explainer on sleep and healthy aging, a correction-aware analysis of Mediterranean dietary evidence and PREDIMED, and a metformin analysis that separates approved diabetes use from unproven healthy-aging claims.
    • Records discovery, counterevidence and claim-level integration separately, with stable source, study, trial, claim, assessment, relationship, provenance, correction and history records.
    • Connects all three stories to Latest, the homepage, category hubs, topics, guides, sitemap, deterministic validation, container smoke tests, and hosted responsive screenshot review.
64. Cycle 34 · July 31, 2026 · started 2:53 p.m. MDT Production verified

    Prepared a second edition of sourced longevity coverage

    This release candidate addresses issue #71 through PR #76.

    • Publishes a CALERIE calorie-restriction Research Brief, a human-senolytic-evidence News Analysis, and an epigenetic-clock Explainer with explicit population, evidence maturity, outcomes, limitations, safety, conflicts, and claim boundaries.
    • Records three separate research passes and traceable PMID, PMCID, DOI, NCT, correction, and DailyMed identifiers in a versioned real-record bundle.
    • Connects all three stories to Latest, the homepage, category hubs, guides, sitemap, deterministic validation, container smoke tests, and responsive screenshot review.
65. Cycle 33 · July 31, 2026 · started 12:53 p.m. MDT Production verified

    Taught readers how methods and models limit a claim

    This release candidate addresses issue #67 through PR #74.

    • Publishes complete guides to research methods and model-to-human translation, organized around practical questions readers can ask of a headline or evidence box.
    • Defines a versioned, storage-independent research-literacy contract with fictional non-medical records, eleven independent dimensions, explicit unknown states, and twenty-two deterministic rejection fixtures.
    • Connects Learn, Research, evidence, article, study, trial, glossary, and orientation routes while prohibiting scores, real-record assessment, ingestion, recommendations, scheduling, and publication.
66. Cycle 32 · July 31, 2026 · started 11:06 a.m. MDT Production verified

    Made updates, corrections, and record history understandable

    This release candidate addresses issue #65 through PR #72.

    • Adds an Updates and history center plus a non-medical record demonstration that separates clarifications, corrections, source updates, status changes, retractions, withdrawals, editorial notes, and product changes.
    • Defines a versioned, storage-independent update-ledger projection with prior and current states, affected routes, source verification, reviewer decisions, append-only history, honest unknown states, and twenty-four deterministic rejection fixtures.
    • Connects the homepage trust area, corrections policy, provenance, record history, monitoring, editorial workflows, topic and article demonstrations while clearly stating that live monitoring, automatic mutation, notification, and publication have not launched.
67. Cycle 31 · July 30, 2026 · started 11:22 p.m. MDT Production verified

    Prepared the first three sourced longevity stories

    This approved release candidate addresses issue #69 through PR #70.

    • Prepares source-reviewed coverage of the ER-100 partial-reprogramming trial, PEARL rapamycin results, and exercise evidence for healthy aging with explicit population, model, evidence maturity, limitations, safety, conflicts, and source roles.
    • Records three separate research passes plus verified DOI, PMID, NCT, regulatory and guidance identifiers in connected article, topic, study, trial, claim, source, provenance, and relationship records.
    • Records David’s July 31 publication approval, rechecks source and correction status, and makes all three routes indexable and reachable from the homepage, Latest, and relevant category pages.
68. Cycle 30 · July 30, 2026 · started 9:10 p.m. MDTProduction verified

    Demonstrated concise Signals and evidence-safe Daily Briefings

    This release candidate addresses issue #63 through PR #68.

    • Adds two fixture-only formats showing how small developments stay proportionate and grouped updates keep independent evidence, sources, corrections, histories, and next actions.
    • Defines a versioned, storage-independent editorial-formats contract with explicit grouping and non-execution boundaries plus deterministic rejection cases.
    • Connects Latest, the homepage, the full article demonstration, and social-signal discovery while making clear that regular reporting, monitoring, scheduling, and daily delivery have not launched.
69. Cycle 29 · July 30, 2026 · started 6:07 p.m. Costa Rica time Production verified

    Mapped the longevity industry without turning activity into evidence

    This release candidate addresses issue #61 through PR #66.

    • Adds a fixture-only Industry orientation spanning organizations, programs, deals, regulation, people, clinics, commercial claims, reporting, disclosures, and evidence boundaries.
    • Defines a versioned, storage-independent Industry projection with eleven independent dimensions and nineteen deterministic rejection fixtures.
    • Connects the homepage, organization and researcher directories, provenance, history, claims, Search readiness, and editorial standards while keeping Industry out of primary navigation until verified real records make that destination useful.
70. Cycle 28 · July 30, 2026 · started 4:38 p.m. Costa Rica time Production verified

    Expanded Learn from evidence decoding to reader orientation

    This release candidate addresses issue #59 through PR #64.

    • Adds Longevity 101, a controlled plain-language glossary, and a general safety-and-scam literacy framework as three connected reader routes.
    • Defines a versioned, storage-independent reader-glossary contract with stable terms, aliases, boundaries, provenance, honest states, and deterministic rejection fixtures.
    • Connects the new orientation from the Learn collection and existing evidence, clinical-trial, and biomarker guides without evaluating a real intervention, product, company, or claim.
71. Cycle 27 · July 30, 2026 · started 4:08 p.m. Costa Rica time Production verified

    Made source intake and identifier checks inspectable

    This release candidate addresses issue #55 through PR #62.

    • Adds two fictional, non-medical demonstrations that separate discovery, source classification, deduplication, identifier normalization, identity matching, and human review routing.
    • Defines a versioned, storage-independent pre-ingestion contract with exact, ambiguous, no-match, invalid, unavailable, stale, corrected, retracted, and rejected states.
    • Adds deterministic rejection fixtures and connects intake from provenance, history, monitoring, Research, Studies, and Trials without calling an external API or enabling publication.
72. Cycle 26 · July 30, 2026 · started 3:08 p.m. Costa Rica time Production verified

    Made evidence review and human approval inspectable

    This release candidate addresses issue #53 through PR #60.

    • Adds two fictional, non-medical workflow demonstrations that separate source checks, scoped evidence review, revision, editorial decisions, and final human publication eligibility.
    • Defines a versioned, storage-independent workflow contract with explicit role, decision, eligibility, provenance, correction, honest-state, and append-only history boundaries.
    • Adds deterministic rejection fixtures and connects the workflow from editorial, article, claim, provenance, history, and corrections routes without enabling a CMS or publisher.
73. Cycle 25 · July 30, 2026 · started 2:48 p.m. Costa Rica time Production verified

    Closed an ISO calendar-date validation gap

    This repair release candidate addresses issue #57 through PR #58.

    • Rejects calendar-impossible ISO-looking dates before JavaScript can normalize them into a different real date.
    • Covers the rollover case with a deterministic 2026-02-30 fixture while preserving valid leap-day, ordinary, UTC, and offset date-time values.
    • Leaves the production JSON-LD graphs, canonical URLs, visible reader content, services, and publication boundaries unchanged.
74. Cycle 24 · July 30, 2026 · started 2:08 p.m. Costa Rica time Production verified

    Made fixture and evidence boundaries readable by machines

    This release candidate addresses issue #51 through PR #56.

    • Adds a versioned, storage-independent structured-metadata contract for conservative Schema.org page, entity, identity, date, role, provenance, and relationship mappings.
    • Adds fixture-only JSON-LD to the article-format, living-topic, and Research routes while keeping evidence assessment, development stage, editorial state, correction state, and fixture status independent.
    • Adds deterministic rejection fixtures for duplicate or dangling identities, unsupported schema, canonical and date mismatches, missing provenance, visible-copy disagreement, false unknowns, and prohibited rating or medical shortcuts.
75. Cycle 23 · July 30, 2026 · started 1:10 p.m. Costa Rica time Production verified

    Made material source-status changes traceable

    This release candidate addresses issue #49 through PR #54.

    • Adds a fixture-only material-status monitoring demonstration that follows detection, identifier matching, verification, affected-record review, and editorial disposition.
    • Keeps source status, match confidence, verification, correction state, affected records, provenance, and history independent without a truth, evidence, or credibility score.
    • Adds a versioned monitoring contract, seventeen deterministic rejection fixtures, Corrections, Editorial standards, provenance, history, Research, and Search integration, metadata, sitemap, container coverage, and responsive QA.
76. Cycle 22 · July 30, 2026 · started 12:09 p.m. Costa Rica time Production verified

    Separated social attention from scientific evidence

    This release candidate addresses issue #47 through PR #52.

    • Adds a fixture-only social-signal discovery demonstration that follows observation, clustering, triage, source verification, and editorial disposition.
    • Keeps discussion level, scientific importance, source role, verification, correction state, provenance, and history independent without an engagement-derived score.
    • Adds a versioned discovery projection contract, sixteen deterministic rejection fixtures, Latest, Research, Search, and Editorial standards integration, metadata, sitemap, container coverage, and hosted responsive QA.
77. Cycle 21 · July 30, 2026 · started 11:11 a.m. Costa Rica time Production verified

    Made article connections transparent and inspectable

    This release candidate addresses issue #45 through PR #50.

    • Adds a fixture-only connected-coverage demonstration that explains why an article points to each durable record.
    • Keeps reports-on, status-update, timeline-event, curated, current, historical, corrected, superseded, unavailable, unknown, and not-assessed states distinct.
    • Adds a versioned recirculation contract, fifteen deterministic rejection fixtures, Latest, Research, Search, article, and topic integration, metadata, sitemap, container coverage, and hosted responsive QA.
78. Cycle 20 · July 30, 2026 · started 7:10 a.m. Costa Rica time Production verified

    Made claim-to-evidence relationships inspectable

    This release candidate addresses issue #43 through PR #48.

    • Adds a fixture-only claim-to-evidence demonstration with a precisely scoped fictional claim and four distinct evidence relationships.
    • Keeps support, contradiction, indirect evidence, insufficiency, study design, population, outcome, limitations, provenance, confidence, and history separate without a composite score.
    • Adds a versioned projection contract, fourteen deterministic rejection fixtures, Research, Search, article, and topic integration, metadata, sitemap, container coverage, and hosted responsive QA.
79. Cycle 19 · July 30, 2026 · started 6:11 a.m. Costa Rica time Production verified

    Made organization and researcher relationships inspectable

    This release candidate addresses issue #41 through PR #46.

    • Adds fixture-only organization and researcher directory demonstrations using fictional, non-medical records.
    • Keeps identity, aliases, programs, dated roles, affiliations, authorship, disclosures, provenance, reporting confidence, corrections, and evidence boundaries independent.
    • Adds a versioned directory projection contract, deterministic rejection fixtures, Research, Search, trust, and discovery integration, metadata, sitemap, container coverage, and hosted responsive QA.
80. Cycle 18 · July 30, 2026 · started 5:08 a.m. Costa Rica time Production verified

    Made source provenance and record history inspectable

    This release candidate addresses issue #39 through PR #44.

    • Adds fixture-only source-provenance and append-only record-history demonstrations using fictional, non-medical records.
    • Keeps source identity, role, verification dates, confidence, editorial status, validity windows, corrections, supersessions, and retractions independent.
    • Adds a versioned projection contract, deterministic negative fixtures, Research and trust-center integration, metadata, sitemap, container coverage, and hosted responsive QA.
81. Cycle 17 · July 30, 2026 · started 4:11 a.m. Costa Rica time Production verified

    Separated study reporting from trial operations

    This release candidate addresses issue #37 through PR #42.

    • Adds distinct fixture-only study-library and clinical-trial tracker demonstrations that explain what each record can show.
    • Keeps study design, publication state, population, outcomes, trial phase, operational status, results availability, evidence, and provenance independent.
    • Adds a storage-independent tracker contract, deterministic negative fixtures, separate linked study and publication identities, Research and discovery integration, metadata, sitemap, container coverage, and responsive QA.
82. Cycle 16 · July 30, 2026 · started 3:10 a.m. Costa Rica time Production verified

    Demonstrated an evidence-aware intervention directory

    This release candidate addresses issue #35 through PR #40.

    • Adds a complete non-medical directory-format preview with one fixture record and ten visibly independent questions.
    • Defines canonical categories, aliases, provenance thresholds, neutral grouping and sorting, stable URLs, and honest empty, unknown, not-assessed, unavailable, and mixed states.
    • Adds deterministic positive and negative fixtures, Interventions integration, metadata, sitemap, container smoke coverage, and hosted responsive QA.
83. Cycle 15 · July 30, 2026 · started 2:09 a.m. Costa Rica time Production verified

    Demonstrated how a living topic page accumulates knowledge

    This release candidate addresses issue #33 through PR #38.

    • Adds a complete fixture-only topic page with Overview, Latest, Evidence, Trials, Companies, and Timeline views that work without JavaScript.
    • Keeps status, development stage, evidence maturity, population, outcome, reporting confidence, publication status, uncertainty, and editorial assessment independent.
    • Adds a storage-independent projection contract, positive and negative fixtures, homepage and Topics integration, metadata, sitemap, container smoke coverage, and responsive QA.
84. Cycle 14 · July 30, 2026 · started 1:08 a.m. Costa Rica time Production verified

    Defined evidence-aware discovery before launching search

    This release candidate addresses issue #31 through PR #36.

    • Adds a versioned, storage-independent discovery contract with labeled result types, thirteen evidence-sensitive facets, canonical aliases, durable query serialization, and honest unavailable, empty, invalid, and no-match states.
    • Publishes a complete search-readiness route without a fake search box, disabled filters, fabricated counts, invented records, or premature primary-navigation promotion.
    • Connects the route from Research and the Topics map and adds deterministic negative fixtures, metadata, sitemap, container smoke coverage, and hosted responsive QA.
85. Cycle 13 · July 30, 2026 · started 12:07 a.m. Costa Rica time Production verified

    Opened research, study, and trial discovery

    This release candidate addresses issue #27 through PR #34.

    • Adds a Research hub that separates sources, study records, trial records, reported results, scientific claims, and reader-facing updates.
    • Adds study- and trial-record guides with explicit fields, evidence boundaries, and honest pre-catalog states—without fabricated records, identifiers, results, or claims.
    • Integrates Research with primary navigation, the homepage, Topics map, metadata, sitemap, deterministic validation, container smoke tests, and hosted responsive QA.
86. Cycle 12 · July 29, 2026 · started 11:10 p.m. Costa Rica time Production verified

    Opened Aging Biology and intervention discovery

    This release candidate addresses issue #25 through PR #32.

    • Adds complete Aging Biology and Interventions orientation hubs, with plain-language scope, evidence questions, and honest pre-coverage states for every category.
    • Adds a Topics map that connects biology, proposed interventions, research Guides, and the article method without fabricating stories, counts, or detail routes.
    • Integrates the new discovery paths with shared navigation, the homepage, metadata, sitemap, deterministic validation, container smoke tests, and hosted responsive QA.
87. Cycle 11 · July 29, 2026 · started 10:10 p.m. Costa Rica time Production verified

    Defined the longevity knowledge-system contract

    This release candidate addresses issue #28 through PR #30.

    • Makes the target navigation, intervention and Aging Biology taxonomies, living topic pages, article evidence structure, formats, cadence, and search facets authoritative.
    • Defines storage-independent entities, first-class claims, relationships, provenance, external identifiers, evidence dimensions, and unknown-value semantics.
    • Adds controlled vocabularies, aliases, a clearly non-medical demonstration bundle, and negative fixtures that deterministic validation must reject.
88. Cycle 10 · July 29, 2026 · started 9:10 p.m. Costa Rica time Production verified

    Rebuilt the homepage as an evidence-aware publication front

    This release candidate addresses issue #23 through PR #29.

    • Gives the editorial-format demonstration a clear lead-story hierarchy while repeating that it is not current reporting.
    • Adds distinct paths into evidence, clinical-trial, and biomarker literacy without implying medical review or a launched news catalog.
    • Makes the evidence methodology, editorial boundary, and public build record easy to find from the homepage.
89. Cycle 9 · July 29, 2026 · started 8:09 p.m. Costa Rica time Production verified

    Built the trust and transparency center

    This release candidate addresses issue #21 through PR #26.

    • Adds distinct About, Editorial standards, and Corrections routes with a cohesive trust-center design and cross-links.
    • Makes the mission, source roles, uncertainty language, disclosures, AI-assistance boundaries, and publication approval boundary visible before regular coverage begins.
    • Defines dated, explained, preserved correction history while honestly stating that no public intake channel exists yet.
90. Cycle 8 · July 29, 2026 · started 7:08 p.m. Costa Rica time Production verified

    Built a practical research-guides collection

    This release candidate addresses issue #20 through PR #24.

    • Adds a complete Guides landing page plus plain-language clinical-trial and biomarker interpretation guides.
    • Separates evidence maturity, trial design, measurement reliability, surrogate status, function, healthspan, and lifespan without analyzing a real intervention or product.
    • Integrates the collection with shared navigation, homepage, metadata, sitemap, deterministic validation, and responsive QA.
91. Cycle 7 · July 29, 2026 · started 6:09 p.m. Costa Rica time Production verified

    Built the evidence-oriented article experience

    This release candidate addresses issue #19 through PR #22.

    • Adds an honest Latest page and a clearly labeled article-format demonstration without publishing a real medical or scientific claim.
    • Makes content status, evidence maturity, study population, reporting confidence, caveats, provenance, disclosures, and update history visible to readers.
    • Integrates both routes with the homepage, shared navigation, metadata, sitemap, deterministic checks, and hosted responsive QA.
92. Cycle 6 · July 29, 2026 · started 5:48 p.m. Costa Rica time Production verified

    Increased the loop’s queue depth and cycle ambition

    This release candidate addresses issue #17 through PR #18.

    • Requires the controller to prepare three dependency-ready issues before a normal build, so claiming one leaves two queued.
    • Raises the normal target to a coherent reader-facing increment spanning roughly one to three related routes and their complete integration and QA.
    • Preserves one active implementation PR, one issue per build, every risk boundary, and every release gate.
93. Cycle 5 · July 29, 2026 · released 5:44 p.m. Costa Rica time Production verified

    Made every content page easier to navigate

    The cycle completed issue #15 through PR #16.

    • Added one consistent Home, Evidence guide, and Development log navigation pattern across every content page.
    • Added a semantic, no-JavaScript mobile menu with large touch targets, visible keyboard focus, and honest current-page state.
    • Added hosted Chromium QA that measures responsive behavior and preserves screenshot evidence; it caught and prevented a real desktop-navigation defect before release.
94. Cycle 4 · July 29, 2026 · started 2:10 p.m. Costa Rica time Production verified

    Made missing pages honest and useful

    The cycle completed issue #7 through PR #14.

    • Added a branded, accessible not-found page with a clear route back to the homepage.
    • Replaced the misleading homepage fallback so unknown URLs return the custom page with an honest HTTP 404 status.
    • Added hosted container checks for existing routes, direct 404-page access, missing-path behavior, and automatic cleanup.
95. Cycle 3 · July 29, 2026 · started 1:10 p.m. Costa Rica time Production verified

    Published a guide to reading longevity evidence

    The cycle completed issue #6 through PR #13.

    • Added a five-rung guide explaining what cell, animal, observational, randomized, and replicated human evidence can and cannot establish.
    • Covered the cross-cutting questions that shape evidence quality, relevance, and practical meaning.
    • Linked the guide from the homepage, added it to the sitemap, and extended deterministic route and content validation.
96. Cycle 2 · July 29, 2026 · 12:26 p.m. Costa Rica time Production verified

    Made the site discoverable and repaired a release defect

    The cycle completed issue #5 through PR #8, then used production QA to find and fix an incorrect web-manifest content type through issue #9 and PR #10.

    • Added crawl rules, a sitemap, canonical URLs, social-sharing metadata, a favicon, a web manifest, and a share card.
    • Extended deterministic validation for the new discovery and sharing assets.
    • Verified both HTML routes and every new asset in production, including the corrected application/manifest+json response.
97. Cycle 1 · July 29, 2026 · released 10:02 a.m. Costa Rica time Production verified

    Established the governed autonomous development loop

    The first manual cycle completed issue #2 through PR #4.

    • Added durable product, architecture, editorial, roadmap, and release-gate guidance.
    • Installed the GitHub queue, controller state, labels, issue template, deterministic site validation, and container CI.
    • Published this development route and verified the homepage and log in production at desktop and mobile sizes.

Issue #213 · Review · Content/evergreen: Explain how primary, secondary and subgroup results answer different questions through PR #218. The sole branch is agent/issue-213-outcome-hierarchy-explainer. The reviewed release candidate passes full local deterministic validation; exact-head hosted responsive evidence and manual inspection are next.

1. Issue #215 · Ready · Product

   Harden Research, Studies and Trials accessibility, metadata and route weight

   Second bounded Phase 4 discovery-route hardening increment; eligible only after #213 production-verifies.

2. Issue #217 · Ready · Content/news

   Report what a randomized kidney-care trial found for frail older adults

   Open-access source-reviewed outcome analysis; remains queued behind #215 and cannot create a concurrent publisher.

Ledger: 13 normal production-verified completions / 9 qualifying content / 4 product. One qualifying content item has completed since the latest product, so #213 is eligible; #215 remains ineligible until #213 production-verifies. Actual production remains 65 stories / 146 publications / 65 registry records / 285 rendered Search records; branch candidate totals are 66 / 146 / 65 / 286. #205 earns zero credit; #183 is deferred.